



**International Journal of TROPICAL DISEASE
& Health**
4(2): 147-181, 2014



SCIENCEDOMAIN *international*
www.sciencedomain.org

Current and Future Trends in the Clinical Diagnosis of Rickettsioses *Sensu Lato*

S. Missailidis^{1*}, D. T. Godoy¹, M. A. M. M. Mares-Guia¹,
A. R. M. Favacho¹ and E. R. S. Lemos¹

¹Laboratório of Hantaviruses and Rickettsioses, Instituto Oswaldo Cruz (IOC), FIOCRUZ,
Rio de Janeiro, Brazil.

Authors' contributions

This work was carried out in collaboration between all authors. Authors SM and DTG contributed equally and share first authorship. All authors read and approved the final manuscript.

Review Article

Received 17th July 2013
Accepted 14th September 2013
Published 20th November 2013

ABSTRACT

Aims: The aim of this review is to present Rickettsioses *sensu lato*, with emphasis on their current and future clinical diagnosis. The review presents the conditions, the agents that cause them, and the current gold standards on their diagnosis in national and international reference centres. Additionally, this review covers the various emerging technologies available in the diagnosis of Rickettsioses and discusses their potential for future use as gold standards in the diagnosis of these diseases.

Introduction: The introduction presents Rickettsioses *sensu lato* and gives a broad overview of the conditions they cause, the issues associated with their current diagnosis and the need for their improved, earlier and more accurate diagnosis, in order to prevent current issues with false negatives, misdiagnosis or delay in the diagnosis associated with these conditions, which often renders them grave or lethal.

Main Body: The main body of the review presents in independent sections Rickettsias, Ehrlichia, Anaplasma, Bartonella and Coxiella and the conditions associated with each of these bacteria. Spotted fever, endemic typhus, human granulocytic anaplasmosis, human monocytic ehrlichiosis, bartonellosis and Q-fever are some of the conditions associated with this group of proteobacteria. The emphasis is on the clinical diagnosis of these conditions and an overview of the current practice, gold standards in reference

*Corresponding author: Email: sotiris.missailidis@ioc.fiocruz.br;

laboratories and improvements in these methodologies is presented. The last part of the review focuses on novel technologies in bacterial detection and their application specifically on Rickettsioses *sensu lato*, demonstrating how these technologies are being applied in this field and how they could improve current standards and resolve issues associated with the clinical diagnosis of rickettsioses.

Conclusion: Rickettsioses *sensu lato* are conditions associated with proteobacteria historically included in the Rickettsiaceae family, able to cause a number of conditions, often grave or lethal. One of the major issues associated with poor clinical outcome is the lack of early and accurate differential diagnostic methodologies. Current methods, including serological and molecular biology techniques have various advantages and disadvantages, which new technologies available or currently in development may be in a position to resolve and the issues associated with the institution of such technologies.

Keywords: Rickettsia; Ehrlichia; Anaplasma; Bartonella; Coxiella; clinical diagnosis.

1. INTRODUCTION

Significant advances in bacterial detection and clinical diagnosis of bacterial diseases have been achieved in the last decade and have opened the path for future developments. However, a lot of bacterial diseases remain misdiagnosed and, despite advances in antibiotics and the availability of curative interventions, they can often lead to serious conditions and death, with diagnosis arriving in very late stages or even post-mortem. One such group of bacteria, where methods for accurate and early diagnosis remain necessary are the "rickettsias *sensu lato*", here referred to as proteobacteria historically included in the Rickettsiaceae family, before phylogenetics investigations that placed genera *Bartonella* and *Coxiella* in other taxonomic subdivisions [1,2]. Besides these, the genus *Orientia*, causing scrub typhus, has recently been removed from the genus *Rickettsia* and classified as a separate genus in the Rickettsiaceae family. *Orientia* is shown to be endemic in eastern Asia and western Pacific, and is transmitted by mites, and is thus not included in this review, as is not *Neorickettsia* and *Wolbachia*.

Various diseases are attributed to "rickettsias *sensu lato*", including rickettsioses of the spotted fever group (SFG), recrudescent typhus, typhus transmitted by cat fleas, rickettsioses varicelliform, ehrlichiosis, Q fever and bartonellosis, transmitted by arthropods, like mites, ticks, lice and fleas, and are found in many parts of the world. *Rickettsia* and *Ehrlichia* genus are α -proteobacteria of the subgroup 1 and *Bartonella* of the subgroup 2, whereas *Coxiella burnetii* belongs to the γ -proteobacteria. Although initially the above species all belonged to the order *Rickettsiales*, family *Rickettsiaceae*, they are now reorganised and considered as individual families of bacteria. The family *Bartonellaceae*, as well as *Coxiella burnetii*, were removed from the order *Rickettsiales*, which includes now two families, the *Anaplasmataceae* and *Rickettsiaceae*. However, they are often still studied within the field of rickettsiology and for the purpose of this review we will consider them jointly, particularly due to the many common characteristics they present, both in the way they are transmitted and in many of the symptoms they cause [1,2].

Rickettsioses, especially SFG, are often misdiagnosed for other endemic diseases, such as dengue fever or leptospirosis, in tropical countries and, thus, often result in grave or fatal outcome [3-5]. This in part is due to the similarity of symptoms with other common endemic diseases, but also in part due to the nature of the diagnostic assays currently employed as gold standards in the diagnosis of these conditions, based on serological assays for the

presence of patient antibodies against these bacteria. As patient antibodies, IgG or IgM, can take up to two weeks to appear, early serological examination may lead to false negative results and two evaluations are necessary. Yet, until the second evaluation takes place to confirm seropositivity, symptoms may have advanced significantly. Thus, in this review, we are looking at "rickettsias *sensu lato*", including, besides the genus *Rickettsia*, the *Ehrlichia*, *Anaplasma*, *Bartonella* and *Coxiella* genus with a focus on the current diagnostic standard and an evaluation of future trends and their applicability and viability as laboratory methods that could have a wider application in the early and accurate diagnosis of these bacterial infections.

2. RICKETTSIOSES CAUSED BY THE GENUS *RICKETTSIA* AND THEIR DIAGNOSIS IN HUMANS

Rickettsioses are zoonoses caused by obligate intracellular bacteria of the genus *Rickettsia* in the order *Rickettsiales*. Rickettsias are Gram-negative, non-motile bacteria, with endothelial cells as their primary target. Their life cycle involves arthropod vectors like ticks, fleas, lice and mites [6]. Members of this genus may be classified into four groups: (i) typhus group (TG), which includes *Rickettsia typhi* and *Rickettsia prowazekii*; (ii) spotted fever group (SFG), based mainly on phenotypic and serological features with more than 25 different species including *Rickettsia rickettsii*, *Rickettsia conorii*, *Rickettsia africae*, and *Rickettsia parkeri*; (iii) ancestral Rickettsiae group, which includes *Rickettsia belli* and *Rickettsia canadensis* and (iv) transitional group, with *Rickettsia akari*, *R. australis* and *R. felis* [7-10].

Rickettsial pathogens are widely distributed throughout the world, causing emerging and re-emerging infectious diseases. These zoonoses are among the oldest known vector-borne diseases. Their global distribution varies according to the density and distribution of the arthropod vector and the population density of the reservoir hosts [6,11]. SFG are increasingly being identified among international travellers. Two percent of imported fevers are caused by rickettsioses and 20% of these patients are hospitalized [12].

The case definition of confirmed SFG includes both clinical evidence and laboratory confirmation. The clinical features of this rickettsiosis consist of an acute undifferentiated febrile illness, often accompanied by headache, myalgia and nausea, and a maculopapular or vesicular rash may be observed a few days after the onset of illness [13-15]. When a patient develops a febrile illness, the suspicion for tick-borne illness should be high in those who live or travel to endemic areas. Outdoor activities, whether recreational or occupational, particularly in areas with high-uncut grass, weeds, and low brush, can increase the risk for tick bites and thus the chance for disease onset [16].

Clinical disease develops prior to an antibody response, so patients presenting clinical evidence of disease due to rickettsial infections, should be empirically treated with appropriate antibiotics, regardless of the outcome of initial laboratory testing [11]. Doxycycline is the treatment of choice for adults and children. Resistance to doxycycline has not yet been reported. Chloramphenicol may be used in cases of life-threatening allergy to doxycycline [17]. Rickettsial organisms are naturally resistant to many antimicrobial drugs routinely used as treatment for acute fevers, including β -lactams. Fluoroquinolones and newer macrolides are useful options of treatment [12]. Several species of SFR have been confirmed as human pathogens and the number is rising. Some examples are: *R. rickettsii*, *R. parkeri*, *R. conorii*, *R. africae*, *R. felis*, *R. japonica*, *R. helvetica*, *R. montanensis*, *R. rhipicephalis* and *R. sibirica*.

Similar SFG, epidemic typhus, caused by *Rickettsia prowazekii*, is also usually associated with more severe symptoms, which typically begin suddenly, and high mortality in the absence of specific treatment. Regarding to endemic typhus, caused by *Rickettsia typhi* and occasionally *R. felis*, its clinical manifestations are also similar to those of SFG, but are less severe and rarely lead to death [6,18].

Diseases caused by agents of the *Rickettsia* genus can be diagnosed in a number of different ways; each approach has its advantages and its limitations. The specific laboratory confirmation could be either detection of specific DNA by PCR, demonstration of the organism in cell culture, or a fourfold rise in antibody titres on paired samples taken 2-4 weeks apart.

Rickettsiae are isolated most commonly from blood, skin biopsy specimens and autopsy tissue fragments or arthropods, especially ticks. Rickettsiae culture must be performed only in biosafety level 3 facilities, which are limited to Reference Centers or few research laboratories in the world [19,20].

Rickettsial antibodies can be detected by complement fixation, latex agglutination, enzyme-linked immunosorbent assay and immunofluorescence assay (IFA). IFA is the gold standard for serological diagnostic of rickettsial infections and it is performed worldwide [21]. Diagnostic criteria of recent infection by IFA test are either a 4-fold increase of immunoglobulin IgG or IgM titres in paired samples drawn \geq seven/10 days apart, or elevated IgG and/or IgM titres in single samples consistent with recent infection. A diagnostic IFA titre of < 64 is not considered positive. A titre of > 64 is considered exposure or probable acute infection without rising titre. Titres should be interpreted based on the background seroprevalence of endemic area [17]. The main limitation with serological diagnosis include a usually negative result in the acute phase when patients first seek medical care, poor sensitivity in cases treated with doxycycline, and an inability to distinguish among various rickettsial species caused by cross-reaction [12].

The greatest challenge to clinicians is not therapy but the difficult diagnosis during the early phase of infections [18]. The diagnosis of rickettsiosis can be missed because of these nonspecific initial clinical presentations and the absence of specific laboratory confirmation [22]. Serological diagnosis is usually retrospective; antibody increase takes 15-26 days, thus limiting the clinical impact of diagnosis [23].

Molecular diagnosis using polymerase chain reaction (PCR) targeting various rickettsial genes has been developed to accelerate the diagnosis of rickettsiosis and allow early species diagnosis. While some PCR target several species, others are designed to detect only a single rickettsial species. The five genes usually targeted by PCR for detection and diagnosis are citrate synthase *glhA*, gene D *sca4*, the 17kDa lipoprotein precursor antigen gene 17kDa, and genes for outer membrane proteins A and B *ompA* and *ompB* [21,24]. Other targeted genes include 16S ribosomal RNA *16S rDNA*, serine peptidase *htrA* [20]. It should be noted that, in contrast to SFG rickettsiae, all rickettsiae belonging to TG (*R. prowazekii* and *R. typhi*) lack the *ompA* gene [25].

Rickettsial diagnosis based on PCR has been used extensively [20,24,26-31]. PCR primer sets, targeting various rickettsial genes, have been described and can be used in any laboratory with suitable facilities. Rickettsiae can be detected from clinical samples including skin biopsies, autopsy tissue fragments, blood and sera. Modifications of the PCR technique

led to its improvement and the development of the nested PCR (nPCR), which increased the sensitivity of PCR to the level of detecting 1-10 genomic equivalents per reaction [32].

Santibáñez and co-workers [20] evaluated the effectiveness of PCR methods to detect *Rickettsiae* from clinical samples. They determined the sensitivity and usefulness of molecular diagnosis targeting the *16S rDNA*, *htrA*, *gltA*, *ompA* and *ompB* genes by PCR. They performed single and sequential (nested or semi-nested) PCR assays. The samples tested were collected from patients in the early phase of the illness before antibiotic therapy. For single PCR assays, the greatest sensitivity to detect rickettsial DNA in clinical samples was obtained using *gltA* (33.3%). Higher sensitivity was achieved using sequential *ompB* PCRs (83.3%). They recommend performing *gltA* and *ompB* PCR assays, followed in positive samples by *ompA* PCR and nucleotide sequence analysis for species identification. The *ompB* PCR detects a high percentage of positive samples and it is effective as a first screening. The *ompA* PCR assay is an accurate method to diagnose and to implicate a new *Rickettsia* species. Combination of three sequential PCR assays (*ompA*, *ompB* and *gltA*) achieved 100% sensitivity [20]. Similarly, Sekeyova et al. [33] monitored clinical samples for *Rickettsia*, *Bartonella*, *Borrelia*, *Coxiella*, *Anaplasma*, *Francisella* and *Diplorickettsia* from patients from Slovakia. They evaluated the seroprevalence by multiple-antigen IFA and confirmed the results with PCR. Serum samples from 50 hospitalized patients with suspected tick-borne diseases were evaluated. As a result, 32% were positive by IFA for spotted fever group rickettsia, but only 10% were confirmed by PCR. The discrepancy between IFA and PCR might be due to the sensitivity linked to the time of collection of the serum samples [33]. Therefore, these assays can provide high accuracy and sensitivity and have been used for the molecular diagnosis of rickettsioses, as well as to identify *Rickettsia* species in new clinical patients.

Newer molecular assays are also available. Pan et al. [18] evaluated the potential of loop-mediated isothermal amplification (LAMP) targeting the *ompB* gene to detect SFG rickettsiae early infection. LAMP is a highly sensitive and specific technique that under isothermal conditions (60-65°C) can generate up to 10⁹-fold amplification in less than one hour. They compared the sensitivity of the *ompB* LAMP assay and general PCR. They found the limits of detection of LAMP and PCR for the *ompB* gene were 5 and 625 copies per reaction, respectively. Thus, the LAMP assay is 125-fold more sensitive than conventional PCR. They also evaluated the clinical applicability of the LAMP assay with clinical samples previously positive by serology or real-time PCR and compared the results of LAMP with nested PCR protocols. LAMP detected 8 of 10 confirmed cases while nested PCR detected none of the positive samples [18]. Thus, LAMP assay is a reliable test and could be an ideal choice for development as a rapid and cost-effective means of detecting SFG rickettsiosis.

Renvoisé et al. [34] evaluated the widespread use of real-time PCR for rickettsial diagnosis. They reported two years of their experience at the French National Reference Center (FNRC) with molecular diagnosis for rickettsial diseases using real-time PCR. They designed a new set of primers and probes to detect TG *Rickettsia*, and SFG *Rickettsia*, such as *R. conorii*, *R. slovaca*, *R. africae* and *R. australis*. Specificity was tested *in silico* using blastN analysis on GenBank and *in vitro* using a panel of 30 rickettsial strains. Sensitivity was determined by 10-fold serial dilution. Primers and probes both sensitive and specific were routinely used for diagnosis of rickettsial infections at FNRC. Among the positive clinical samples, 68.9% (31/45) were cutaneous biopsies, 17.8% (8/45) were cutaneous swabs, 4.4% (2/45) were total blood samples and 8.9% (4/45) were serum samples [34]. Based on these findings, it appears that real-time PCR could also be an option that can be

easily implemented in laboratories that have molecular facilities and its widespread use is inexpensive and reduces the delay of rickettsial diagnosis.

Angelakis et al. [35] performed a comparison between cell culture techniques and PCR for the diagnosis of *Rickettsia* infections. They analyzed skin biopsies and ticks collected from patients with suspected *Rickettsia* infections. They identified the presence of *Rickettsia* spp. in skin biopsies and ticks using molecular methods and cell culture. Culture methods were less sensitive than PCR. Culture sensitivity was low in patients under antibiotic treatment because of the high susceptibility of *Rickettsia* to antimicrobial agents. They found a positive correlation between the bacterial copies and the isolation success. Early antibiotic treatment, prior to skin biopsies, reduced the sensitivity of both methods tested [34]. As a result of these studies, it is suggested that PCR would be a much more promising as a reference laboratory technique than cell cultures that are less sensitive and much more demanding, and can also be affected by previous treatments.

A duplex real-time PCR, targeting the DNA of any rickettsial species and TG *Rickettsia* in clinical samples (skin biopsies) has also been developed [23]. The test was sensitive for at least 10 DNA copies per reaction and exhibited good reproducibility. The results from clinical samples allowed an early diagnosis of spotted fever in two cases and recognition of murine typhus in another. Despite the limited number of samples tested, the clinical experience with the duplex real-time PCR assay is encouraging. The recognition of typhus group rickettsia is clinically and epidemiologically relevant, as these infections may be associated with worse prognosis than spotted fever.

3. HUMAN GRANULOCYtic ANAPLASMOSIS, HUMAN MONOCYtic EHRLICHIOSIS AND THEIR DIAGNOSIS

Intracellular bacteria of the Anaplasmataceae family cause ehrlichiosis and anaplasmosis. *Ehrlichia* and *Anaplasma* species are transmitted through the bite of an infected nymph, or adult tick vector that had been previously infected in larval or nymph stage while feeding on a rickettsial animal, known as a reservoir host. Their agents are maintained in nature through enzootic ticks as well as wild and domestic animals [11,36].

The causative agents of human monocytic ehrlichiosis (HME) and human granulocytic anaplasmosis (HGA) are small, Gram-negative, obligate intracellular bacteria that have tropism for specific leukocytes. HME has an affinity for monocytes and HGA preferentially infects granulocytes. They replicate within vacuoles in these leukocytes forming microcolonies called morulae, which allows the organisms to avoid phagocytosis to facilitate their survival [11,37,38].

Clinical presentations of ehrlichiosis and anaplasmosis are similar and nonspecific. HGA and HME are acute febrile tick-borne diseases. Fever is followed by headache, myalgia and arthralgia. Less common symptoms include nausea, abdominal pain, diarrhoea and cough. A rash may be present in 10-30% of cases of HME but is uncommon in HGA, present in less than 10% of infected patients. Neurologic symptoms, including meningitis and meningoencephalitis, have been reported in approximately 20% of patients with HME. Laboratory findings include leukopenia, thrombocytopenia, elevated serum aminotransferase levels, and elevated creatinine levels [37,38,39].

The diseases are considered as emerging and the number of reported cases has been growing due to better diagnostic techniques and surveillance programs [36]. Accurate

diagnosis of many tick-borne diseases is hampered owing to similar clinical manifestations, overlapping geographical distributions and shared vectors. Laboratory confirmation can be carried out using a number of microbiological, serological and molecular techniques [37].

Direct visualization of bacterial inclusions, termed morulae, in the cytoplasm of infected circulating leukocytes can allow rapid diagnosis of *Ehrlichia* spp. and *Anaplasma* spp. [11,37,40]. Morulae detected in neutrophils are indicative of infection by *Anaplasma phagocytophilum*, while detection in monocytes delineates infection by *Ehrlichia chaffeensis* [37]. However, the low level of morulae, the short duration of rickettsemia, and the need of an experienced microscopist limit the utility of this approach.

Recovery of *E. chaffeensis* and *A. phagocytophilum* in mammalian cell culture can also be used to diagnose infection. *A. phagocytophilum* is usually cultivated in the human promyelocytic leukemia cell line HL-60 and the canine histocytic cell line DH28 is employed for culturing *E. chaffeensis* [37,41,42]. Limitations of cell culture as a diagnostic tool include the need of an antibiotic-free environment for growing these cell lines and technical staff trained in cell culture techniques. Besides, with this approach, it can take several days to obtain a positive result.

The indirect immunofluorescence assay (IFA) is the gold standard method proposed by the World Health Organization Collaborating Centre for Rickettsial Reference and Research. Antibodies in the serum bind to fixed antigens on a slide and are detected by a fluorescein-labelled conjugate. The greatest limitation of IFA is the need of a pair of serum samples from both acute and convalescent stages of the illness; which is not applicable as an early test for infection [18]. Nonspecificity can occur in IFA due to cross-reactivity. The Centers for Diseases Control and Prevention recommend that diagnoses based on serological tests should be confirmed by molecular methods [40].

A number of European countries have been confirmed as a hotspot for HGA and rickettsial diseases. Thus, Cochez and co-workers [43] presented results from a 10 years (2000-2009) study of *A. phagocytophilum* sero-surveillance in Belgium. Serum samples from 1350 patients were tested using an IFA IgG and IgM antibody test kit, according to the manufacturer's specifications (Focus Diagnostic, CA, USA). In total, 111 confirmed cases were detected. All cases had a history of tick bite, fever, and initially showed a titre of at least 64, which increased to 256 or higher in their follow-up sample. Based on these findings, the authors suggest that Belgium is a hot spot for HGA infections [43].

A number of clinical samples were also evaluated in France and positive results were identified both with spp. and *Ehrlichia* spp. during acute infection. Several conserved genes have been employed as PCR targets, including the *rrs* (16S rRNA) and *groESL* (heat shock operon). Koebel and co-workers [44] highlight the PCR assay on EDTA-blood samples as the diagnostic test of choice during acute phase of diseases. A Taqman-based real-time PCR was applied to amplify a 73-bp fragment from the *A. phagocytophilum msp2/p44* gene. They report confirmation of three consecutive clinical cases with HGA by Real-time PCR in eastern France [44]. Similarly, Edouard et al. [45] also reported five new human cases of *A. phagocytophilum* infection diagnosed by serology and Real-Time PCR. Serum specimens were tested with microimmunofluorescence assays using a large panel of antigens, including *A. phagocytophilum*. Serum samples were also screened with primers and probes targeting 102-bp of DNA polymerase I of *A. phagocytophilum*. A positive result was confirmed using primers and probes targeting a 92-bp fragment of the glutamyl tRNA amidotransferase gene.

Clinical samples were obtained retrospectively (2000-2010) from the archives of the National Reference Centre for Rickettsioses, Marseille, France [45].

Weil et al. [46] described a tick-associated pathogen panel (TAPP) that includes a PCR assay for the detection of the organisms that cause HGA, other human ehrlichioses (*A. phagocytophilum*, *E. chaffeensis*, and *E. ewingii*), as well as *Borrelia burgdorferi* and *Babesia microti*, the causative agents of Lyme disease and babesiosis, respectively. The PCR targeted *HSPD1*, an open reading frame gene segment of the heat shock protein operon (*groESL*). From 692 samples tested, 33 presented an HGA-positive result. Serological assays were not included in this study [46]. The results of the authors would also suggest the potential of PCR for bacterial detection in the evaluation of more than one organism, even though they have not presented serological evidence for comparison.

Other currently proposed molecular detection methods include LAMP to detect *A. phagocytophilum* in clinical samples [47]. They developed a LAMP assay based on a conserved region in the *msp2* gene. The limits of detection of LAMP compared to PCR were 25 copies of *msp2* gene and 625 copies, respectively. Forty-two clinical samples were tested by LAMP and results were compared with nested-PCR and Real-time PCR. Twenty-six tested positive by LAMP assay while only one and three samples tested positive by nested-PCR and Real-time PCR, respectively. Thus, as shown earlier for rickettsias, LAMP is a rapid, simple, sensitive, and cost-effective assay for detecting *A. phagocytophilum* in clinical samples.

4. BARTONELLA AND ITS DIAGNOSIS

Bartonella species are small, fastidious, intracellular, Gram-negative rod-shaped bacteria belonging to α -Proteobacteria subgroup 2, with a worldwide distribution, which cause an increasingly large number of infectious diseases in humans and animals [48]. In 1993, Brenner and colleagues proposed to unify *Bartonella* and *Rochalimaea* genera and renamed some species as *Bartonella quintana*, *B. henselae*, *B. vinsonii* and *B. elizabethae*. As a result of this unification, the transfer of these organisms from the *Rickettsiaceae* family to the *Bartonellaceae* family was required and, at present, more than 31 species and subspecies are recognized [49].

Several hematophagous insects have been implicated in *Bartonella* transmission, including sand flies [50], the human body louse [51], the cat flea [52] and, potentially, ticks [53,54]. *Bartonella* infections have been encountered in all species surveyed, which extend to members of different orders of mammalian, including carnivores, primates, ungulates, rodents, and bats. It is believed that the vector preference for certain hosts can influence the transmission of these organisms and that is responsible for the association of a given *Bartonella* sp. with a specific host, i.e., *B. henselae*, *B. clarridgeiae* and *B. koehlerae* with cats, *B. alsatica* with wild rabbits, *B. bacilliformis* and *B. quintana* with humans [55,56].

Bartonellae have been recognized as agents causing human disease, including *B. bacilliformis* (agent of Oroya fever and verruga peruana), *B. henselae* (agent of cat scratch disease CSD, bacillary angiomatosis, bacillary peliosis, endocarditis) and *B. quintana* (agent of trench fever, bacillary angiomatosis, bacteremia and endocarditis) and *B. elizabethae* (agent of endocarditis), among others [55]. The *Bartonella* spp. infection can cause great diversity of clinical manifestations in humans, including recurrent fever and fever of unknown origin, malaise, fatigue, insomnia, loss of memory, psychiatric disorders, lymphadenopathy,

splenomegaly, angiomas and bacillary peliosis, endocarditis, hepatitis, osteomyelitis, encephalitis, meningitis, and other neuroretinites [57,58].

The genus *Bartonella* has pathogenic characteristics, such as the ability to invade and lyse red blood cells. Besides erythrocytes, the endothelial cells represent another target of *Bartonella* in their mammalian hosts [56]. Current opinion is that these cells serve as a primary niche for bartonellae prior to them entering the bloodstream. After five days, these bacteria are released into the bloodstream and then are able to invade erythrocytes, where occurs their intracellular replication [59].

Antimicrobials have been used widely in the treatment of bartonellosis. A study using azithromycin in CSD showed a benefit in lymph node regression in 30 days, as compared with placebo [60]. In immunocompromised patients the antimicrobials indicated are erythromycin, clarithromycin, azithromycin, doxycycline, either co-administered or not with rifampicin, and the period of treatment ranges from 4-6 weeks [60,61]. In the acute febrile phase of Carrión's disease the preferred treatment has been chloramphenicol [62], but oral ciprofloxacin has been increasingly and successfully used [61].

Several laboratory methods must be used in bartonellosis diagnostic to avoid false negatives; there is no gold standard [63]. Diagnostic techniques for infections with *Bartonella* spp. include serology by immunofluorescence (IFA) to detect antibodies against the bacteria in the patient's serum, culture of the pathogen, histopathological examination of lymph nodes or tissue biopsy of skin, liver or other affected organs, and molecular biology techniques, especially PCR, to amplify *Bartonella* spp. genes from patient's tissue fragments or blood [64,65].

Serology is particularly important because it allows the rapid identification of *Bartonella* spp. [64,66]. But it is limited by cross-reactions between the different species of *Bartonella*, and also between genera such as *Coxiella* and *Chlamydia* [67,68]. Many studies have shown that serological differentiation between *B. henselae* and *B. quintana* through IFA is impossible, since cross-reactivity between these species is very high (95%). The heterogeneity among strains and genotypes of *Bartonella* spp., might result in differences between the parameters of laboratory analysis and subjectivity of the readings of the results of IFA, which could result in false positives [69,70]. Despite these limitations, IFA remains the gold standard for the diagnosis of infection [68,71].

ELISA method has been proposed as an alternative to IFA. Several ELISA protocols use sonically disrupted *B. henselae* (whole cell-proteins) or the putative outer membrane proteins (OMPs) as the antigens [72,73]. However, studies have demonstrated low sensitivity of ELISA-based serodiagnosis when compared with IFA. Thus, researchers have focused their efforts on the improvement of the antigen preparation for use in IgG ELISA. Tsuruoka et al. [73] found that sarcosine-soluble proteins of *B. henselae* are significantly more specific than whole-cell or sarcosine insoluble proteins as antigens for IgG ELISA, indicating an improvement in accuracy of diagnosis of Bartonella infection [73].

The diagnosis of *Bartonella* infection should be confirmed by culturing the organism from aseptically obtained patient samples, including blood, CSF, lymph nodes, or other tissue aspiration samples, ocular exudates, and from surgical biopsies [58]. The liquid culture of *Bartonella* spp. is necessary to increase the sensitivity of detection of bacteraemia through molecular methods and is one of the most used methods of diagnosis worldwide [74,75,76]. The isolation of most species of *Bartonella* in blood agar plates requires a long incubation

period (6-8 weeks) at 35°C in a water saturated atmosphere containing 5% CO₂. The development of a new liquid culture medium called BAPGM (*Bartonella* Alpha-Proteobacteria Growth Medium) that allows the growth of at least seven *Bartonella* species enabled the improvement of this method as diagnosis. It is now widely used as a pre-enrichment stage and, combined with molecular methods, increased the success and sensitivity of culture for diagnosis in both animals and humans [74-77]. However, to date, there is no consensus regarding the best culture medium or best antigen to be used in the diagnosis of bartonellosis.

Likewise, a consensus has not been achieved on the best gene to be used for primer development and optimal conditions to be used in PCR. Species-specific PCR has been useful, especially when a particular diagnosis is already suspected. Thus, several studies describe regions of the 16S *rRNA* gene, the 16S-23S *rRNA* intergenic spacer region-encoding gene (ITS), citrate synthase gene (*gltA*), the riboflavin synthase (*ribC*), the 60-kDa heat shock protein gene (*groEL*), the N-terminal region of the cell division protein gene (*FtsZ*) or gene of the beta subunit of RNA polymerase (*rpoB*) as the most efficient and promising primer targets for detection of different species of *Bartonella* [48,74].

Besides the set of primers that determine the region to be amplified and therefore the sensitivity of the reaction, the type of PCR also influences the success of the diagnosis. The nested PCR can greatly increase the sensitivity of detection, as does the real-time PCR [76,78]. A semi-nested PCR has also been designed to amplify the gene of a 31-kDa major protein (*Pap31*) associated with the bacteriophage harboured in *B. henselae* [79]. The main advantages of this technique are that it is easy and reliable, culture independent and almost all bacteria can be detected in a single reaction [67]. A limitation of the system is the quality of DNA of some clinical materials, high host DNA concentrations that interferes with DNA amplification of the *Bartonella* target and potential DNA contamination [64].

An important study conducted by La Scola et al. [80] using sequences available in the GeneBank database, compared seven gene targets, specifically the 16S *rDNA*, *gltA*, *groEL*, *rpoB*, *ftsZ*, *ribC* and the internal transcribed spacer 16S-23S (ITS). This comparison demonstrated the relative discriminatory power of each gene examined, and only two genes – *gltA* and *rpoB* – were able to clearly differentiate all species and subspecies of *Bartonella* analysed [80].

Newer molecular approaches in microbiology are available for characterization and typing of *Bartonella* genotypes [81]. The most widely used are pulse field gel electrophoresis (PFGE) [82], multilocus sequence typing (MLST) [83,84], multispacer typing (MST) and multilocus variable number tandem repeat analysis (MLVA) [81].

5. Q FEVER AND *COXIELLA BURNETII* DIAGNOSIS IN HUMANS

Coxiella burnetii is a small, obligate intracellular, gram-negative, pleomorphic bacterium of the order Legionellales and is the cause of Q fever. *Coxiella burnetii* is very stable in the environment in its sporoid form. In natural infections, *Coxiella* has a tropism for cells of the mononuclear phagocytic class, such as lung alveolar macrophages, Kupffer cells of the liver and, more rarely, pneumocytes, fibroblasts and endothelial cells [85].

Coxiella burnetii exists in two antigenic phases, called phase I and phase II. In nature, the *C. burnetii* phase I expressed antigen is observed in humans, infected animals and arthropods and it is the infectious form of the bacterium. The phase II variant is obtained after several

passages in embryonated eggs or cell cultures and is less virulent [86]. The abnormally high resistance against chemical and physical factors, due to endospore formation, is one of the most impressive attributes of *C. burnetii*. It enables this organism to persist in the environment for long periods of time and remain infectious. The surviving ability of the organism, its resistance to heat, desiccation and many disinfectants, justifies its high infectivity, a fact that makes this proteobacteria a possible weapon of bioterrorism and an agent classified as category B. Studies show that a single inhaled organism may produce clinical disease [87,88].

Cattle, sheep and goats are the primary reservoirs of *C. burnetii*. Infection is known in a wide variety of other animals, including other species of ruminant domestic animals as well as wild animals [2,89]. The reservoirs of *C. burnetii* include mammals, birds and arthropods, especially ticks [90]. *Coxiella burnetii* does not usually cause clinical symptoms in these animals, although abortion in goats and sheep may be related to infection by this microorganism that is excreted in the milk, urine and feces of infected animals. During the time of birth of the animals, *C. burnetii* is present in great quantity in the amniotic fluid and placenta. Transmission to humans usually occurs through inhalation of contaminated aerosols from urine, feces, milk, amniotic fluid, placenta, abortion products, wool, or less commonly by drinking raw milk from infected animals [89]. This broad spectrum of unique reservoirs and resistance of *C. burnetii* to environmental factors makes, as mentioned previously, tracing the source of infection very difficult [91].

Infection with *C. burnetii* may present clinical manifestations of acute or chronic Q fever, a disease with a wide spectrum of clinical manifestations, ranging from limited febrile illness, pneumonia, hepatitis and other forms of infections, such as endocarditis, and meningoencephalitis [92,93]. The acute Q fever in humans is asymptomatic in almost 60% of infected people. Among the 40% of symptomatic patients, the majority (38% of 40%) undergo a mild disease without requiring hospitalization. In symptomatic patients, the onset is usually abrupt, with high fever, fatigue, chills and headaches. The most frequent clinical manifestation of acute Q fever is probably a self-limiting febrile disease associated with intense headache. Atypical pneumonia is also a frequent clinical presentation and clinical symptoms can vary from asymptomatic pneumonia, diagnosed by chest radiography, and rarely severe pneumonia resulting in acute respiratory failure. Hepatitis is another common presentation of acute Q fever detected biochemically by increased levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase. Hepatomegaly may be clinically detectable, but jaundice is rare [2].

Q fever can be considered chronic with the persistence of clinical manifestations for more than 6 months after the beginning of the symptoms. It occurs in approximately 5% of patients infected with *C. burnetii* and may develop insidiously over months to years after the acute illness. Patients with cardiovascular abnormalities are at higher risk of developing chronic infection. Normally, the heart is the organ most commonly involved, followed by arteries, bones and liver. Endocarditis usually occurs in patients with previous valvular lesions, or those who are immunocompromised, months or years later, and primarily with the involvement of the aortic valve [86]. Granulomatous hepatitis with a more protracted course can also be observed in some patients and the diagnosis is only possible by liver biopsies. Renal involvement with glomerulonephritis has also been described in Q fever [91,94,95]. Thus, endocarditis, vascular infections, osteoarticular infections, chronic hepatitis, chronic lung infections, chronic fatigue syndrome, prematurity in pregnancy and abortion are some of the clinical presentations that result from chronic infection. Coxiolemlia event results in permanent production and hence very high levels of antibodies in the circulation.

The difference in clinical presentation of Q fever can be explained by: (i) the route of infection by *C. burnetii*, including aerosol, or gastrointestinal tract, (ii) the dose of inoculation of *C. burnetii*, (iii) the variant of infective *C. burnetii*, and (iv) host factors, including immune status of the infected patient [2].

In contrast to acute Q fever in human, animal infection with *C. burnetii* is in most cases so amazingly asymptomatic. This fact implies that the term coxiellosis is considered a more appropriate than animal Q fever. In animals during acute phase, *C. burnetii* can be found in the blood, lungs, spleen and liver, while during the chronic phase *C. burnetii* is presented as a persistent release of the organism in feces and urine [96].

The reservoirs of *C. burnetii* are numerous, including mammals, birds and biological vectors (ticks). Forty species of ticks or more are naturally infected with *C. burnetii*, but are not important in the maintenance of infections in domestic animals and in humans [2]. *Coxiella burnetii* multiplies in intestine cells of ticks and a large number of viable organisms are eliminated through feces. Contaminated leather and wool become vehicles to transmission to people either by direct contact or through the dry feces, inhaled as dust particles suspended in the air [96]. Although it appears that wild rodents are an important reservoir, the most commonly identified source of human infection is farm animals such as cattle, goats and sheep. Pets, including cats, dogs and rabbits can also be potential sources of urban outbreaks. It is suspected that cats are a major reservoir of *C. burnetii* in urban areas. In Canada, studies have shown that 6-20% of cats have anti-*C. burnetii* antibodies [86].

Infected animals eliminate *C. burnetii* through urine, feces and milk products. The occurrence of infection reactivation in female mammals during pregnancy can result in abortions in goats and, to a lesser extent, in sheep, and cause reproductive problems in cattle. *C. burnetii* is located in the uterus and mammary glands of infected animals. High concentrations of *C. burnetii* (up to 10^9 bacteria per g of tissue) have been found in placentas, as well as in the milk of infected animals, although this form is probably less effective in spreading Q fever [2,86,96].

Q fever is a major public health problem in many countries especially in France [97] but also in Spain [98] and the Netherlands, where more than 3,500 cases were reported in the last three years [99-103]. *Coxiella burnetii* is responsible for 5-8% of cases of infective endocarditis in the south of France and Q fever cases occur in 50 per 100,000 inhabitants in this area [2,66,90,104,105,106]. More recent data show that throughout the French territory, the annual incidence of acute Q fever and endocarditis is 2.5/100,000 and 0.1/100,000 persons, respectively [97].

Since the first publication on the emergence of Q fever in the Netherlands, thousands of cases have been reported [101,107-115] and the study of small ruminants demonstrated that the same genotype *C. burnetii* identified in these animals was responsible for the epidemic of Q fever in the Netherlands [101]. Yet another study, conducted by Klaassen et al. [116], identified five genotypes of *C. burnetii* in six patients and six animals from three different regions of the Netherlands [116]. Based on the Q fever epidemic occurred in the Netherlands, the application and importance of an efficient surveillance system, aimed at early identification, has been emphasized [101,113].

The first case of Q fever in Brazil was described in 1953, and, despite being a worldwide zoonosis, remains neglected. Q fever is not a notifiable disease, perhaps because of the lack of human and animal clinical histories. Incidence and epidemiology remains unknown

and the scarce information on the serological evidence in humans and animals is restricted to the states of Bahia, Minas Gerais, Rio de Janeiro and São Paulo [117-123]. The first case of Q fever in Brazil, confirmed by molecular analysis, was reported in the rural area of Itaboraí, Rio de Janeiro State, in 2008, when the patient reported a contact with products of goats' abortion [124]. Further study confirmed the presence of the antigen in the milk of goats and the serum of two dogs that had been fed non-pasteurized milk from these goats, confirming the origin of the source of infection of the patient [125]. According to Rozental et al. [126], the occurrence of Q fever in urban areas confirms the need to include its diagnosis in clinical cases compatible with a history of contact with childbirth or abortion material of pets like dogs and cats [126].

As with all zoonotic diseases, the animal disease control will influence the level of disease observed in humans. Appropriate strategies of tick control and good hygiene practices can reduce environmental contamination. Fluid and foetal membranes infected, aborted foetuses and contaminated bedding materials should be incinerated or buried after disinfection. Furthermore, manure must be treated with lime or calcium cyanide 0.4% before being spread on the fields, which must be done in the absence of wind to prevent the spread of the microorganism over long distances. Treatment of animals with antibiotics may be performed to reduce the number of abortions and the releasing *C. burnetii* in offsprings. Although it can be expensive, infected animals should be removed from or placed in confinement herds separated at birth. Workers from the animal industry should be fully informed about the risk factors for contracting Q fever and laboratories should be provided with adequate safety devices and equipment [96].

In relation to animals, the antibiotic treatment using tetracycline during the last month of pregnancy can reduce the number of abortions and the number of released *C. burnetii* in offspring. The efficacy of this treatment has never been assessed accurately but has not been proven to prevent abortion or completely eliminate the release of *C. burnetii* in newborns [127]. Similarly, regular pasteurization at 72°C for 15 seconds or sterilization of milk from infected flocks is recommended, even though oral is not the major route of transmission of *C. burnetii* [128].

As it has become clear above, the main characteristic of Q fever is its clinical polymorphism, and thus diagnosis can only be made by systematic tests. Clinically, it is likely that factors such as the route of infection and the size of the inoculum determine, in humans, the expression of infection by *C. burnetii*. In fact, the airway is associated with pneumonia, and the gastrointestinal tract with hepatitis [96], while high inoculations are associated with myocarditis [2].

With respect to laboratory diagnosis, Q fever may be detected by serological or molecular methods as well as isolation and histopathology associated with immunohistochemistry techniques. In cases of acute Q fever, antibody levels of phase II are usually higher than those of phase I, often by several orders of magnitude, and usually are first detected during the second week of infection. In the chronic phase the situation is reversed and antibodies to phase I antigens of *C. burnetii* have higher titres, requiring long time to appear and thus indicate continued exposure to the bacteria. In this context, high levels of antibodies to phase I samples later on, in combination with constant or falling levels of phase II antibodies and other signs of inflammatory disease may suggest chronic Q fever. It is known that antibodies against antigens of phase I and II persist for months or years after initial infection [2,96]. Since the clinical diagnosis is difficult, in most cases the diagnosis of Q fever depends

on serological tests. A variety of serological techniques are available, but the indirect microimmunofluorescence test became the reference technique [96].

A real-time PCR assay for the detection of *C. burnetii* DNA in serum samples, targeting the IS1111 transposase sequences (also known as *htpAB*-associated repetitive element) [129], was used in the Netherlands and in Brazil to diagnose acute Q fever early in infection to avoid delay in treatment that can lead to increased hospital admission rates and prolonged morbidity. Researchers found the latest time point after onset of disease in which *C. burnetii* could be detected by PCR of serum samples was day 17 [126,130]. During the last years, several PCR-based diagnostic assays were developed to detect *C. burnetii* DNA in cell cultures and in clinical samples. These assays used conventional PCR, nested PCR or real-time PCR conditions with Light-Cycler, SYBR Green or TaqMan chemistry [96,131]. The Light-Cycler Nested PCR (LCN-PCR), a rapid nested PCR assay that uses serum as a specimen and the Light-Cycler as a thermal cycler, targeting a multicopy 20-copy *htpAB*-associated element sequence, has been adapted for the diagnosis of both acute and chronic Q fever [96,132]. The LCN-PCR assay may be helpful in establishing an early diagnosis of chronic Q fever [90, 96]. Due to its high sensitivity and specificity, the repetitive element IS1111 is the best target gene for the detection of *C. burnetii* in patients with active Q fever [132], although the complete sequences of the genome of *C. burnetii* have recently become available, allowing a large choice of DNA targets.

Recently developed techniques such as MLVA and SNP typing have shown promise and improved the discrimination capacity and utility of genotyping methods for molecular epidemiologic studies of this challenging pathogen [133].

Initial typing systems described were based on plasmid types. Restriction fragment length polymorphisms (RFLP) were analyzed with SDS-PAGE, pulsed-field gel electrophoresis (PFGE), and sequence studies of single genome targets like *16s/23s*, *com1*, *mucZ*, and *icd*. They showed different levels of discriminatory power and epidemiological significance, but all suffered with problems of inter- and intra-laboratory reproducibility, hampering their widespread use [133]. Other techniques that are used for plasmid typing (four different plasmids QpH1, QpRS, QpDV, and QpDG are utilized) include Multispacer Sequence Typing (MST), a method based on the analysis of the intergenic regions of genomes, Single Nucleotide Polymorphism (SNPs), Infrequent Restriction Site-(IRS)-PCR, Microarray-Based Whole-Genome Comparisons/Typing and the IS1111-insertion sequence, coding for a transposase seen in up to 56 copies in *C. burnetii* genomes [133].

6. ALTERNATIVE AND NOVEL APPROACHES TO BACTERIAL DETECTION

6.1 Bacterial Imaging

One method that has been growing in the detection of bacterial infections is the use of imaging. This has been achieved by the use of various imaging techniques and includes nuclear medicine approaches, nuclear magnetic resonance (NMR), optical probes, fluorescent and near-infrared imaging. A number of probes have been developed for the imaging of inflammation, including labelled monoclonal and polyclonal antibodies, cytokines, liposomes, leucocytes, antimicrobial peptides and antimicrobial agents among others [134,135]. The advantage of using nuclear medicine approaches is the differentiation between bacterial and viral infections, or inflammation due to infection with microbial pathogens (bacteria, fungus etc.) and inflammation due to immune response where no

microbial invasion is present, as is the case for example in autoimmune disorders [135]. This is achieved through the radiolabelling of antibiotics or other antimicrobial agents and their subsequent use as imaging agents. The advantage of using labelled antimicrobial agents as the localising agent for infection is the selective toxicity of these agents for microbial rather than human targets and the ability to bind selectively to those, offering the potential to rapidly distinguish a particular type of infection and differentiate it from others, thus influencing clinical decisions and therapeutic approaches [135]. Various antibiotics of broad-spectrum activity have been labelled to date, all or most of them with the radionuclide technetium 99m (^{99m}Tc), a radionuclide widely used in nuclear medicine. These antibiotics include ciprofloxacin (also known as ^{99m}Tc -Infecton), sparfloxacin, enrofloxacin and ceftizoxime. Other agents used in bacterial imaging that are not antibiotics include ^{99m}Tc -ubiquicidin, a cationic synthetic peptide [136,137] and [^{125}I] FIAU 1-(2'-deoxy-2'-fluoro-b-D-arabinofuranosyl)-5-[^{125}I] iodouracil, a substrate for bacterial thymidine kinase present in most bacteria [138,139].

Magnetic resonance imaging (MRI) is another imaging technique that offers the ability to visualise in real time the bacterial infections *in vivo* and study the impact of antibiotics on the bacterial proliferation and viability. The majority of MRI applications are in the detection of bacterial-associated conditions, such as bacterial meningoencephalitis [140], bacterial pyomyositis [141] or bacterial abscesses [142]. However, labelling of MRI probes has led to the development of MRI imaging directly for bacteria. Thus, *Bifidobacterium longum* and *Clostridium novyi-NT* were labelled with super paramagnetic iron oxide nanoparticles and they were subsequently followed by MRI [143]. Similarly, *P. aeruginosa* was labelled with green fluorescent protein (GFP) and was followed *in vivo* with magnetization transfer contrast MRI with excellent results, as it was shown able to be used to track bacterial proliferation and potentially gene expression *in vivo* [144].

Optical imaging of bacterial infection has also been developed, but it is primarily focused on the use of generic reporters, such as light-emitting enzymes (luciferase) and fluorescent proteins such as GFP. However, more specific probes offer the advantage of specific bacterial recognition. As molecular probes, in similar approaches to those described in nuclear medicine techniques, antibodies, sugars, bacteria-binding peptides and antibiotics have been used with varying results. In addition, a synthetic zinc (II) dipicolylamine (Zn-DPA) coordination complex has been used as affinity group in bacterial imaging studies labelled with a carocyanine dye. The complex has been able to stain the periphery of both Gram-positive (*Staphylococcus aureus*) and Gram-negative (*Escherichia coli*) bacteria, giving clear images of the infection site and with no obvious side effects to the host. This technique would be easy to use and could have applications in infections at sites within the tissue penetration limit of the NIR light, such as skin, throat, urinary tract etc. Furthermore, altering the probes could offer more specific bacterial imaging [145].

Bacterial imaging has already been used in the area of rickettsioses, and in particular in the diagnosis of bartonellosis and cat scratch disease (CSD). It is known that ocular manifestations occur in 5%-10% of patient with CSD and several imaging modalities can be used to assist in the diagnosis and management of ocular CSD. They include colour fundus photography that allows the clinician to monitor the fundus changes in this disease, fluorescein angiography that demonstrates leakage at the optic nerve in CSD neuroretinitis and optical coherence tomography to provide confirmation in early stages of neuroretinitis before the formation of a macula star [146].

6.2 Bacterial Identification using Spectroscopic and Spectrometric Techniques

Mass spectrometry has found a number of applications in the identification of bacteria. Some have been used coupled with molecular biology techniques for bacterial typing [147,148], whilst others have been used for the detection of pathogens. MALDI time of flight (TOF) mass spectrometry can offer a robust automated methodology for bacterial analysis, based on the detection of patterns of protein masses and potentially genotyping of single nucleotide polymorphisms for additional accuracy of identification [149].

Eshoo et al. [150] developed a multilocus PCR and electrospray ionization mass spectrometry (PCR/ESI-MS) method for the detection of bacterial tick-borne pathogens, including *Ehrlichia* and *Anaplasma*, in blood specimens. The role procedure of PCR/ESI-MS assay can be completed within six hours. The assay employs 16 primer pairs, including four broad-range primer pairs targeting the 16S and 23S genes of all bacteria. The other primers were selected based on their coverage groups of known tick-borne bacteria. Following PCR, the amplicons are analysed in an electrospray ionization mass spectrometer. Two hundred and thirteen clinical specimens from suspected ehrlichiosis patients were included in the study. This demonstrated the ability of PCR/ESI-MS to correctly diagnose the pathogen responsible for ehrlichiosis and identify it to species level [150].

Fourier transform infrared (FTIR) spectroscopy is another spectroscopic technique that has found extensive use in bacterial detection. It has been used for bacterial analysis since the 1980s, and a lot of different types of bacteria have been investigated by FTIR, including *Listeria*, *Bacillus*, *Staphylococcus*, *Clostridium*, *E. coli* and *Lactobacillus* [151]. The authors presented the differential discrimination of *Listeria innocua*, *Listeria welshimeri*, *Escherichia coli* K12, *Escherichia coli* ATCC 29181, *Salmonella choleraesuis*, *Salmonella subterranean*, *Enterobacter sakazakii* and *Enterobacter aerogenes*. They have managed to accurately identify the microorganisms, even in complex backgrounds containing other bacterial populations, and differentiate bacteria even within the same genotype independently of growth phase [151].

Several groups have been specialising on the FTIR detection of pathogens and bacteria in particular. Such works were characterised by the detection and characterisation of particular molecular groups of the bacteria, such as lipopolysaccharides from *E. coli* strains [152], to the identification of bacteria such as *E. coli* O157:H7 and *Salmonella typhimurium* [153]. Additionally, bacteria have been detected by FTIR in complex media, such as *E. coli* O157:H7 in fruit juices [154], ground beef [155] and *Salmonella enterica* serovars in chicken breast [156].

In addition to the ability to differentiate between different bacterial cells in complex environments, FTIR has provided the possibility to identify treated and un-treated, or live and dead cells of the same bacteria [157]. Bacterial typing and subtyping at the haplotype level has also been described for *Listeria monocytogenes* [158] and *E. coli* O157:H7 isolates [159]. Finally, FTIR detection has been used in sensor development [160,161], amongst a number of other detection techniques, some of which will be briefly mentioned below on the biosensor section for bacterial detection.

FTIR remains a promising methodology that could be of interest in the detection of rickettsiosis, but so far it has been limited to applications in food borne pathogens. However, wider exploitation of this methodology could also offer a rapid and accurate detection and

typing methodology. Detection limit mentioned is 4.8-5.8 log CFU/ml. (about 100,000-500,000 bacteria/ml), when upper acceptable limit for bacteria in milk is 200.000/ml. That would, for example be of potential interest in the detection of *Coxiella* in milk.

6.3 Microarrays

One interesting approach to bacterial detection, and rickettsial detection in particular, that may offer differential diagnostic and simultaneous analysis of various samples, could be with the use of microarrays. A number of microarrays have been developed so far, based on the printing of a recognition element on a slide and subsequent detection of a signal. The recognition element can be protein, antibodies, carbohydrates or nucleic acids and different types of arrays have been resulted from the use of the above elements, with different scales of success. Thus, carbohydrate arrays have been described [162], where five different aminofunctionalised monosaccharide derivatives have been printed onto glass slides and the specific binding of fluorescently labelled *E.coli* ORN178 to mannose was observed. Furthermore, the array was shown to be able to differentiate between different strains of *E. coli* with differential affinity to mannose, and a detection limit of 10^5 - 10^6 cells. On a similar approach, Wang et al. [163] have developed a carbohydrate microarray with 48 microbial polysaccharides for the specific recognition of carbohydrate-binding antibodies in the serum of patients. They were able to identify the particular type of infection based on the detection of patient antibodies with unique affinity for a specific pathogen polysaccharide, and with this methodology they successfully identified infections from *E. coli* and *Pneumococcus* and can be extended to a number of other pathogenic bacteria [163].

A similar, but somewhat reverse approach is the use of microarrays with lectins, to capture specific carbohydrate chains on the surface of bacterial cells. Most pathogenic bacteria possess cell surface polysaccharide or lipopolysaccharide shells, with crucial functions for their protection from the immune system and host invasion. Exploiting the natural affinity of lectins for bacterially expressed polysaccharides, lectin microarrays have been produced and utilised for bacterial detection. Lectins have been printed on glass slides and incubation with fluorescently labelled bacteria offered profiling of the diverse glycan structures [164,165,166] according to the specific binding of lectin to the lipopolysaccharide. As bacteria can specifically and reproducibly bind to certain lectins, such arrays can offer the potential to specifically differentiate bacterial species, or strains of the same bacterium with differential affinities to the specific lectin [164,167].

Protein microarrays have also been reported and, using antibodies as recognition agents, microarrays were able to detect *E. coli* and *Renibacterium Salmoninarum* [168]. One of the important characteristics of this work was the signal detection by scanning probe microscopy (SPM), whose high resolution imaging demonstrated the high binding selectivity of the antibodies for the specific bacteria, compared to signal from non-specific, control ones [168]. However, the most widely applied microarrays remain DNA microarrays. This has been primarily due to the technological developments that allow synthesis of oligonucleotides on the surface of the array directly and high-density printing. A number of commercial arrays are currently available, such as those available from Agilent, which allow up to a million oligonucleotide probes printed on a single slide. Other commercially available arrays include those from Affymetrix, NimbleGen, CombiMatrix, Oxford Gene Technologies, etc. Bacterial detection based on oligonucleotide arrays has been an active field of research and development for more than one decade, with reports of bacterial detection of a conserved bacterial gene in 2001 [169], species identification [170] and genotyping of bacterial pathogens using epidemiological markers [171-173].

Oligonucleotide arrays have been used in bacterial detection in a number of formats and for a number of applications. In rickettsial diseases, there has been use of microarrays in two different forms. First of all, based on the whole genome sequence of *R. prowazekii*, the Rickettsial Diseases Division of the U.S. Naval Medical Research Center constructed the first rickettsial microarray with all predicted ORFs. The genomic compositions of virulent strain and attenuated strain were studied by co-hybridization on this DNA microarray [174]. They have also deposited a patent for the detection and diagnosis of *R. prowazekii* infection, but this time by measuring the increased or decreased expression of specific human genes following infection, using DNA microarrays and PCR. This method permits the detection of the rickettsial infection and diagnosis of epidemic typhus earlier than other available methods [175]. Another DNA array for *R. prowazekii* has also been generated, which was the first DNA microarray for the analysis of global gene expression changes in *R. prowazekii* under stress conditions [176]. In addition to *R. prowazekii*, other *Rickettsia* microarrays are available based on rickettsial genomic information. The *Rickettsia* Genome microarray from Agilent Technologies, comprising probes specific to all genes and spacers from *R. prowazekii*, was used by Bechah et al (2010) for the genomic, proteomic and transcriptomic analysis of *R. prowazekii* [177]. The genome of *R. rickettsii* str. 'Sheila Smith' has also been provided and used for the development of a database containing 3205 oligonucleotides that represent the *R. rickettsii* 'Sheila Smith' transcriptome [178]. Within the same database for pre-designed oligonucleotide microarray probes, available to the research community, are included the sequences for specific strains of *R. rickettsii*, *R. africae*, *R. akari*, *R. bellii*, *R. canadensis*, *R. conorii*, *R. felis*, *R. massiliae*, *R. peacockii*, *R. prowazekii*, and *R. typhi* [178].

Finally, even this very year there has been a further development in bacterial detection by microarrays by Ballarini et al. [179] with the creation of the BactoChip microarray. Whereas the majority of microarrays use the 16S rRNA gene for diagnosis, the BactoChip uses 60-mer probes against an *in silico* identified set of genes. In so doing, BactoChip has been able to distinguish successfully among bacterial species from 21 different genera and determine the species-level relative abundances of 37 clinically relevant bacteria in complex bacterial communities and with a low detection limit of 0.1% [179]. Although "rickettsias *sensu lato*" are not included in this microarray, it is only a matter of time until an array containing rickettsias, either alone or amongst other bacteria with similar clinical manifestations, is created.

Apart from changing the probes on the microarrays and using a variety of molecules that have affinity for different bacterial parts, or using oligonucleotide probes against bacterial genes, there is significant development on signal detection and enhancement. The majority of microarrays are based on fluorescent detection. However, we already saw above the use of SPM for improved signal detection [168]. Other such techniques for improved detection include Resonance-Light Scattering (RLS), Planar-Waveguide Technology (PWT) [180], Infrared detection [181,182] and electrical or electrochemical detection [183].

6.4 Biosensors

Biosensor technology holds great promise for the health care market, environmental diagnostics, the food industry and the veterinary sector; harnessing the specificity and sensitivity of biological-based assays packaged into portable and low cost devices which allow the rapid analysis of complex samples in out-of-laboratory environments. Numerous biosensors have been described for bacterial identification, based on a number of detection technologies and recognition elements. Thus, bacterial sensors have been characterised based on their transducer properties, which include surface plasmon resonance (SPR),

amperometric, potentiometric, and acoustic wave sensors [184]. These sensors have been independently reviewed in Zourob, Elwary and Turner (2008) [185] in individual chapters, including SPR [186], Evanescent Wave-based Fluorescent biosensors [187], Fiber Optic biosensors [188], Integrated Deep-Probe Optical Waveguides [189], Interferometric biosensors [190], Luminescence sensors [191], Porous and planar silicon sensors [192], Acoustic wave biosensors [193], Amperometric biosensors [194], Field Effect Transistors [195], Impedance-based sensors [196], Molecular Nanowire transducer-based sensors [197], Magnetic sensors [198], Cantilever sensors [199], Raman spectroscopy [200], and others.

The main biological sensing materials used in biosensor development are the couple antibody/antigen [201]. Yet, a number of other recognition elements are currently used, which include nucleic acid diagnostics [202], aptamers [203], molecularly imprinted polymers [204], phage display methods [205], bacteriophages [206,207]. An excellent representation of bacterial sensors and a review of progress of bacteriophage use in bacterial sensors are presented by Singh et al. [208], where the majority of types of sensors, including that of nucleic acids and antibodies are presented, in addition to bacteriophages, and tables of sensors available for specific microorganisms. Part of nucleic acid based sensors utilise a number of the techniques available in common molecular detection assays, such as PCR or real-time PCR amplification and subsequent detection of amplification products, but in a lab-on-chip format with integrated microfluidic platform systems and various transducer/detection methodologies, reviewed by Lui et al. [209].

There have not, as yet, appeared specific sensors for rickettsial diseases in the literature. However, a number of the currently available sensor methodologies would apply to the detection of rickettsias as well as the organisms they were originally designed for, or have used as exemplars. To that effect, a number of patents on sensor development for bacterial detection have already included rickettsias in their list of pathogenic organisms potentially detected by the patented sensor technology. Two such examples are the design of electrochemical sensors including electrode systems with increased oxygen generation [210,211], where the invention describes the development of systems and methods for electrochemical analyte detection based on increased oxygen generation. Though the initial idea is to measure glucose, the patent proposes to cover a number of other 'contemplated analytes', one of which is rickettsia. In a similar case, a transcutaneous analyte sensor is described by Brister et al. [212], for measuring analytes in a host. In that invention, it is specified that the analyte is used in a broad sense, to include, without limitation, reaction products, naturally occurring substances, artificial substances, metabolites and/or reaction products and it subsequently specifies an extensive, but not limiting list of chemicals, products and microorganisms that the sensor could be applied for, including rickettsia, and thus protecting the use of such sensors in rickettsial diseases.

There are, however, two specific references to rickettsial pathogen detection. One is on a document from the US Office of Scientific and Technical Information (OSTI) of the Department of Energy (DOE), where Andy Hatch describes the development of the first ultrasensitive microanalytical diagnostic method for rickettsial pathogens [213]. In the published summary of his report, he states the use of *in situ* polymerised porous polymer monoliths as size exclusion elements for capture and processing of rickettsial infected cells from a sample and as a photopatternable framework for grafting high densities of functionalised antibodies and fluorescent particles. With this, they have achieved selective capture and identification of bacterial cells with at least an order of magnitude improvement in the detection limits of currently available methodologies and reduced detection times

[213]. The second direct reference to the development of rickettsial sensors is again from the US, with the award of a programme for the development of 'Handheld Aptamer-Magnetic Bead-Quantum Dot Sensor for Rickettsiae' from the US Department of Defence (Small Business Innovation Research SBIR website) [214]. In this programme, they have proposed to use a previously developed sensor format for *Campylobacter jejuni* developed by Operational Technologies, that uses a rapid and ultrasensitive one-step plastic adherent DNA aptamer-magnetic bead plus aptamer-quantum dot sandwich assay to detect the bacteria in a handheld battery operated fluorimeter sensor that can be operated under field conditions. The group has now proposed to develop aptamers against a mixture of isolated rickettsias and substitute those used for the *Campylobacter* detection on the same sensor. No further data have been found to date regarding the outcome of this project.

The existence of these two efforts clearly demonstrates the applicability of sensor development for rickettsial diseases and it may prove to be a practical route to an economically viable and rapid diagnostic approach that would offer definitive response without the need for extensive laboratorial work and long waiting times for patient immune response, at least as a first approach, prior to confirmation by molecular techniques.

6.5 Aptamers

Aptamers offer an interesting and promising new approach for the detection of bacteria and the development of new assays that could offer a more rapid and accurate detection. They are, in effect, recognition elements that can be selected against any target of interest, bacterial proteins, DNA or entire bacterial cells, and be integrated into any of the potential new methodologies described above. Thus, aptamers have been used in molecular imaging techniques, labelled with radionuclides [215,216] for the diagnostic imaging of disease. Similarly, aptamers have been used in a number of microarray formats and in conjunction with various detection methodologies. For example, RNA aptamers have been used in conjunction with enzymatically amplified surface plasmon resonance imaging for the detection of protein biomarkers [217]. Similarly, aptamers have been used in microarrays for the capture of biomarkers in serum to be analysed and identified by Mass Spectrometry [218]. Aptamers have also been described in biosensor applications, as seen earlier on [203, 219]. In addition to their use in such more novel approaches to detection, they have directly substituted antibodies in more traditional approaches, such as ELISA, and have been used in conjunction with antibodies in sandwich ELISAs [220] and in the bacterial detection of *Francisella tularensis* in what is described as an aptamer-linked immobilized sorbent assay - ALISA [221].

Aptamers have been utilised extensively in the development of sensors for bacterial detection and there is an extensive list of bacteria that have been used as targets of aptamers and aptamer sensor development for detection and bacterial typing. Some examples include *Salmonella* species [222-224], *E. coli* [224,225], *Staphylococcus aureus* [224,226], *Bacillus anthracis* and *Bacillus thuringiensis* [227], *Pseudomonas aeruginosa* [228], *Listeria monocytogenes* [229], *Francisella tularensis* [221], among others.

Despite the number of bacterial targets, both those used in diagnostic sensor development, as those mentioned above, and others used in the development of riboswitches, there have not been as yet any aptamers reported against rickettsias. However, *B. henselae* has been used as negative control, to show that aptamers were specific for *F. tularensis* but they did not bind to the related *Bartonella* [221] and, finally, they have appeared as the target in the development of the first rickettsial sensor by Jonh Bruno [214]. And as aptamers can be

applied in a variety of formats and can substitute antibodies in the more established and well-accepted ELISA and immunofluorescence assays, as well as in the variety of sensor development and microarray approaches, they show a great promise for bacterial diagnosis and detection of rickettsial infections in particular.

7. CONCLUSION

It is a big challenge for clinicians to offer an accurate diagnosis of rickettsial diseases during the early phase of infection. The gold standard serodiagnostic, immunofluorescence assay, is usually retrospective. The sensitivity of this method range from 84 to 100%, but it is limited by cross-reactivity. Antibodies increase takes more than 10 days, thus limiting the clinical impact of diagnosis. The isolation of rickettsia organisms in cell culture also take several days. Besides this, laboratory facilities with biosecurity level 3 are required. Molecular methods, based on PCR, for the diagnosis of human rickettsiosis allow rapid detection at the acute phase of infection and identification of bacterial species, even in small amount of the agent. Multiplex or Real-Time PCR can combine the detection of two or more agents of tick-borne infection into a single diagnostic test. Blood, serum, autopsy tissue fragments and skin biopsies specimens can be used as clinical samples to detect the rickettsial infection in molecular methods. The sensitivity of molecular method assays is linked to time of collection of clinical samples, the rickettsiemia level and is limited by the use of antibiotic therapy.

Various new approaches to the traditional assays have offered improvements to serologic and molecular diagnostic methods, which prove to be more sensitive than previous conventional methods. Thus, a novel enrichment liquid culture medium promotes the growth of *Bartonella* species in a shorter period, increasing the bacterial detectable level for PCR detection. The test double amplification (nested PCR), when compared with culture and simple PCR, is a more sensitive and faster method to detect bacteremia in both humans and animals. The use of combined approaches is also often necessary to minimize the chance of negative false results. Emphasizing that there is no gold standard for the diagnosis of bartonellosis and the difficulty of detecting bacteremia caused by *Bartonella* spp. increases the need to use different and complementary methods to increase the sensitivity and accuracy of diagnosis.

Various novel methodologies have for a long time being developed by research laboratories on the area of biosensors, microarrays, imaging methods or spectroscopic techniques, but most of them have not yet made it to the market, or at least they have not been accepted as techniques used in reference laboratories worldwide. According to Jeanne Moldenhauer [230], industry has been reluctant to follow scientific and technological advancements in the development of rapid/alternative microbiological methods due to two major reasons. One was the concern that regulators would not recognise or accept these methods in place of traditional methods. The other was that companies would not be allowed to change test limits based upon the test method, i.e. they would use a superior method that was likely to detect more organisms and not be allowed to adjust the limits to accommodate for the sensitivity of the new method [230]. Yet, it is likely that these inhibitions will necessarily be overcome, due to the limitations to current methodologies. Thus, DNA and aptamer microarrays could offer simultaneous detection of multiple parasites with similar broad clinical manifestations, and thus avoid misdiagnosis and wrong treatment, often detrimental for the patient. Similarly, direct ELISA or ALISA (aptamer-based ELISA type assay), if available, could eliminate the time necessary in rickettsioses for the detection of patient antibodies, and the need for double measurements to confirm infection. Finally, biosensor and aptasensor technologies could offer the possibility of early detection with cheap and

approachable diagnostic assays at the clinic or the field, rather than the need for all material to be analysed only at national reference centres. Thus, aptamers and sensor technologies that are currently in development could play a pivotal role in the detection and early treatment of rickettsial disease, thus significantly reducing the death toll associated with these infections and contributing to public health improvement.

CONSENT

Not applicable.

ETHICAL APPROVAL

Not applicable.

ACKNOWLEDGEMENTS

Dr Sotiris Missailidis and Dr Daniella Tupy de Godoy would like to thank CNPq for financial support.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Brenner DJ, O'Connor SP, Winkler HH, Steigerwalt AG. Proposals to unify the genera *Bartonella* and *Rochalimaea*, with descriptions of *Bartonella quintana* comb. nov., *Bartonella vinsonii* comb. nov., *Bartonella henselae* comb. nov., *B. elizabethae* comb. nov., and to remove the Family *Bartonellaceae* from to order *Rickettsiales*. Int J Syst Evol Microbiol. 1993;43:711-15.
2. Maurin M, Raoult D. Q Fever. Clin Microbiol Rev. 1999;12(4):518–53.
3. Zavala-Velazquez JE, Yu XJ, Walker DH. Unrecognized spotted fever group rickettsiosis masquerading as dengue fever in Mexico. Am J Trop Med Hyg. 1996;55(2):157-59.
4. Rozental T, Eremeeva ME, Paddock CD, Zaki SR, Dasch GA, Lemos ERS. Fatal case of Brazilian spotted fever confirmed by immunohistochemical staining and sequencing methods on fixed tissues. Ann N Y Acad Sci. 2006;1078:257–59.
5. Lamas C, Favacho A, Rozental T, Bóia MN, Kirsten AH, Guterres A, et al. Characterization of *Rickettsia rickettsii* in a case of fatal Brazilian spotted fever in the city of Rio de Janeiro, Brazil. Braz J Infect Dis. 2008;12(2):149-51.
6. Parola P, Paddock CD, Raoult D. Tick-borne rickettsioses around the world: Emerging diseases challenging old concepts. Clin Microbiol Rev. 2005;18:719-56.
7. Vitorino L, Chelo IM, Bacellar F, Zé-Zé L. *Rickettsiae* phylogeny: a multigenic approach. Microbiology. 2007;153:160-68.
8. Walker DH, Ismail N. Emerging and re-emerging rickettsioses: endothelial cell infection and early disease events. Nat Rev Microbiol. 2008;6:375-86.
9. Valbuena G, Walker DH. Infection of the endothelium by members of the order *Rickettsiales*. Thromb Haemost. 2009;102:1071–79.

10. Kantsø B, Svendsen CB, Jørgensen CS, Krogfelt KA. Comparison of two commercially available ELISA antibody test kits for detection of human antibodies against *Coxiella burnetii*. Scand J Infect Dis. 2012;44:489-94.
11. Nicholson WL, Allen KE, McQuiston JH, Breitschwerdt EB, Little SE. The increasing recognition of rickettsial pathogen in dogs and people. Trends Parasitol. 2010;26:205-12.
12. Jensenius M, Davis X, Von Sonnenburg F, Schwartz E, Keystone JS, Leder K, et al. For the GeoSentinel Surveillance Network. Emerg Infect Dis. 2009;15:1791-98.
13. Renvoisé A, Raoult D. L'actualité des rickettsioses. Med Mal Infect. 2009;39:71-81.
14. Basra G, Berman MA, Blanton LS. Murine typhus: An important consideration for the nonspecific febrile illness. Case Rep Med. 2012;ID134601.
15. Gehrke FS, Angerami RN, Marrelli MT, Souza ER, Nascimento EMM, Colombo S, et al. Molecular characterization of Mediterranean spotted fever rickettsia isolated from a european traveller in the State of São Paulo, Brazil. J Travel Med. 2013;20:54-56.
16. Decker CF. When to suspect tick-borne illness. Dis Mon. 2012;58:330-34.
17. Lin L, Decker CF. Rocky mountain spotted fever. Dis Mon. 2012;58:361-69.
18. Pan L, Zhang L, Wang G, Liu Q. Rapid, simple and sensitive detection of the *ompB* gene of spotted fever group rickettsia by loop-mediated isothermal amplification. BMC Infect Dis. 2012;12:254-60.
19. Brouqui P, Bacellar F, Baranton G, Birtles RJ, Bjørnsdorff A, Blanco JR, et al. Guidelines for the diagnosis of tick-borne bacterial diseases in Europe. Clin Microbiol Infect. 2004;10:1108-32.
20. Santibáñez S, Portillo A, Santibáñez P, Palomar AM, Oteo JA. Enfermedades infecciosas y microbiología clínica. 2012; <http://dx.doi.org/10.1016/j.eimc.2012.08.001>
21. Kantsø B, Svendsen CB, Jørgensen CS, Krogfelt KA. Evaluation of serological tests for the diagnosis in Denmark. J Microbiol Methods. 2009;76:285-88.
22. Gehrke FS, Angerami RN, Marrelli MT, de Souza ER, do Nascimento EM, Colombo S, et al. Molecular characterization of Mediterranean spotted fever rickettsia isolated from a European traveller in the state of São Paulo, Brazil. J Travel Med. 2013;20(1):54-6.
23. Giulieri S, Jatón K, Cometta A, Trelu LT, Greub G. Development of a duplex real-time PCR for the detection of *Rickettsia* spp. And typhus group rickettsia in clinical samples. FEMS Immunol Med Microbiol. 2012;64:92-7.
24. Prakash JAJ, Lal TS, Rosemol V, Verghese VP, Pulimood SA, Reller M, et al. Molecular detection and analysis of spotted fever group *Rickettsia* in patients with fever and rash at a tertiary care center in Tamil Nadu, India. Pathog Glob Health. 2012;106:40-45.
25. Wölfel R, Essbauer S, Dobler G. Diagnostics of tick-borne rickettsioses in Germany: A modern concept for neglected disease. Int J Med Microbiol. 2008;298:368-74.
26. Kuloglu F, Rolain JM, Akata F, Eroglu C, Celik AD, Parola P. Mediterranean spotted fever in the Trakya region of Turkey. Ticks Tick Borne Dis. 2012;3:297-303.
27. Torina A, Fernandez de Mera IG, Alongi A, Mangold AJ, Blanda V, Scarlata F, et al. *Rickettsia conorii* indian tick typhus strain and *R. slovaca* in humans, Sicily. Emerg Infect Dis. 2012;18:1008-10.
28. Favacho ARM, Rozental T, Calic SB, Scofield MAM, Lemos ERS. Fatal Brazilian spotless fever caused by *Rickettsia rickettsii* in a dark-skinned patient. Rev Soc Bras Med Trop. 2011;44:395-96.
29. Zhang L, Ni D, Feng Z. External quality assessment of the detection of rickettsioses in China. Asian Pac J Trop Med. 2010:851-54.

30. Nilsson K. Septicaemia with *Rickettsia helvetica* in a patient with acute febrile illness, rash and myasthenia. *J Infection*. 2009;58:79-82.
31. Zavala-Castro J, Zavala-Velázquez J, Walker D, Pérez-Osorio J, Peniche-Lara G. Severe infection with *Rickettsia felis* associated with hepatites in Yucatan, Mexico. *Int J Med Microbiol*. 2009;299:529-33.
32. Richards AL. Worldwide detection and identification of new and old rickettsiae and rickettsial diseases. *FEMS Immunol Med Microbiol*. 2012;64:107-10.
33. Sekeyova Z, Subramanian G, Mediannikov O, Diaz MQ, Nyitray A, Blaskovicova H, et al. Evaluation of clinical specimens for *Rickettsia*, *Bartonella*, *Borrelia*, *Coxiella*, *Anaplasma*, *Franciscella* and *Diplorickettsia* positivity using serological and molecular biology methods. *FEMS Immunol Med Microbiol*. 2012;64:82-91.
34. Renvoisé A, Rolain JM, Socolovschi C, Raoult D. Widespread use of real-time PCR for rickettsial diagnosis. *FEMS Immunol Med Microbiol*. 2012;64(1):126-9.
35. Angelakis E, Richet H, Rolain J-M, La Scola B, Raoult D. Comparison of real-time quantitative PCR and culture for the diagnosis of emerging rickettsioses. *PLoS Negl Trop Dis*. 2012;6:e1540.
36. Doudier B, Olano J, Parola P, Brouqui P. Factors contributing to emergence of *Ehrlichia* and *Anaplasma* spp. as human pathogens. *Vet Parasitol*. 2010;167:149-54.
37. Thomas RJ, Stephen Dumler J, Carlyon JA. Current management of human granulocytic anaplasmosis, human monocytic ehrlichiosis and *Ehrlichia ewingii* ehrlichiosis. *Expert Rev Anti Infect Ther*. 2009;7:709-22.
38. St. Clair K, Decker CF. Ehrlichioses: Anaplasmosis and human ehrlichiosis. *Dis Mon*. 2012;58:346-54.
39. Dahlgren FS, Mandel EJ, Krebs JW, Massung RF, McQuiston JH. Increasing Incidence of *Ehrlichia chaffeensis* and *Anaplasma phagocytophilum* in the United States, 2000–2007. *Am J Trop Med Hyg*. 2011;85:124-31.
40. Centers for Disease Control and Prevention. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis — United States: a practical guide for physicians and other health-care and public health professionals. *MMWR*. 2006;55(No. RR-4):1-36.
41. Standaert SM, Yu T, Scott MA, Childs JE, Paddock CD, Nicholson WL, et al. Primary isolation of *Ehrlichia chaffeensis* from patients with febrile illnesses: clinical and molecular characteristics. *J Infect Dis*. 2000;181:1082-88.
42. Goodman JL, Nelson C, Vitale B, Madigan JE, Dumler JS, Kurtti TJ, et al. Direct cultivation of the causative agent of human granulocytic ehrlichiosis. *N Engl J Med*. 1996;334: 209-15.
43. Cochez C, Ducoffre G, Vandenvelde C, Luyasu V, Heyman P. Human anaplasmosis in Belgium: A 10-year seroepidemiological study. *Ticks Tick Borne Dis*. 2011;2:156-59.
44. Koebel C, Kern A, Edouard S, Hoang AT, Celestin N, Hansmann Y, et al. Human granulocytic anaplasmosis in eastern France: clinical presentation and laboratory diagnosis. *Diagn Microbiol Infect Dis*. 2012;72:214-18.
45. Edouard S, Koebel C, Goehringer F, Socolovschi C, Jaulhac B, Raoult D, et al. Emergence of human granulocytic anaplasmosis in France. *Ticks Tick Borne Dis*. 2012;3:402-04.
46. Weil AA, Baron EL, Brown CM, Drapkin MS. Clinical findings and diagnosis in human granulocytic anaplasmosis: A case series from Massachusetts. *Mayo Clin Proc*. 2012;87:233-39.
47. Pan L, Zhang L, Wang G, Liu Q, Yu Y, Wang S, Yu H, He J. Rapid, simple and sensitive detection of *Anaplasma phagocytophilum* by loop-mediated isothermal amplification of the *msp2* gene. *J Clin Microbiol*. 2011;49:4117-20.

48. Anderson BE, Neuman MA. *Bartonella* spp. As emerging human pathogens. Clin Microbiol Rev. 1997;10:203-19.
49. Kaiser PO, Riess T, O'Rourke F, Linke D, Kempf VA. *Bartonella* spp: throwing light on uncommon human infectious. Int J Med Microbiol. 2011;302:7-15.
50. Caceres AG. Geographic distribution of *Lutzomyia verrucarum* (Townsend, 1913) (díptera, Psychodidae, Phlebotominae), vector of human bartonellosis in Peru. Rev Inst Med Trop Sao Paulo. 1993;35(6):485-90.
51. Roux V and Raoult D. Body lice as tools for diagnosis and surveillance of re-emerging disease. J Clin Microbiol. 1999;37:596-99.
52. Higgins JA, Radulovic S, Jaworski DC, Azad AF, Acquisition of the Cat Scratch Disease Agent *Bartonella henselae* by Cat Fleas (*Siphonaptera: Pulicidae*). J Med Entomol. 1996;33: 490-495.
53. Sanogo YO, Zeaiter Z, Caruso G, Merola F, Shpynov S, Brouqui P, et al. *Bartonella henselae* in *Ixodes ricinus* ticks (*Acari: Ixodida*) removed from humans, Belluno province, Italy. Emerg Infect Dis. 2003;9:329-32.
54. Billeter SA, Levy MG, Chomel BB, Breitschwerdt EB. Vector transmission of *Bartonella* species with emphasis on the potential for tick transmission. Med Vet Entomol. 2008;22:1-15.
55. Breitschwerdt EB, Kordick DL. *Bartonella* infection in animals: carriership, reservoir potential, pathogenicity, and zoonotic potential for human infection. Clin Microbiol Rev. 2000;13:428-38.
56. Birtles R. *Bartonellae* as elegante hemotropic parasites. Ann NY Acad Sci. 2005;1063:270-79.
57. Chomel BB, Boulois HJ, Maruyama S, Breitschwerdt EB. *Bartonella* spp. in pets and effect on human health. Emerg Infect Dis. 2006;12:389-94.
58. Breitschwerdt EB, Maggi RG, Chomel BB, Lappin MR. Bartonellosis: an emerging infectious disease of zoonotic importance to animals and human beings. J Vet Emerg Crit Care. 2010;20:8-30.
59. Harms A, Dehio C. Intruders below the radar: molecular pathogenesis of *Bartonella* spp. Clin Microbiol Rev. 2012;25:42-78.
60. Bass JW, Freitas BC, Freitas AD, Sisler CL, Chan DSF, Vincent JM, et al. Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. Pediatr Infect Dis. 1998;17:447-452.
61. Rolain JM, Brouqui P, Koehler JE, Maguiña C, Dolan MJ, Raoult D. Recommendations for treatment of human infections caused by *Bartonella* species. Antimicrob Agents Chemother. 2004;48:1921-23.
62. Maguiña C, Guerra H, Ventosilla P. Bartonellosis. Clin Dermatol. 2009;27:271-80.
63. Maggi RG, Mascarelli PE, Pultorak EL, Hegarty BC, Bradley JM, et al. *Bartonella* spp. bacteraemia in high-risk immunocompetent patients. Diagn Microbiol Infect Dis. 2011;71:430-37.
64. Houpikian P, Raoult D. Diagnostic methods current best practices and guidelines for identification of difficult-to-culture pathogens in infective endocarditis. Cardiol, 2003;21:207-17.
65. Lamas C, Curi A, Boia MN, Lemos ERS. Human bartonellosis: seroepidemiological and clinical features with an emphasis on data from Brazil – A Review. Mem Inst Oswaldo Cruz. 2008;103:221-35.
66. Houpikian P, Raoult D. Blood culture-negative endocarditis in a reference center: etiologic diagnosis of 348 cases. Medicine (Baltimore). 2005;84:162-173.
67. Fournier PE, Raoult D. Nonculture laboratory methods for the diagnosis of infectious endocarditis. Curr Infect Dis Rep. 1999;1:136-41.

68. Maurin M, Rolain JM, Raoult D. Comparison of in-house and commercial slides for detection of immunoglobulin G and M by immunofluorescence against *Bartonella henselae* and *B. quintana*. Clin Diagn Lab Immunol. 2002;9:1004-09.
69. Sander A, Berner R, Ruess M. Serodiagnosis of cat-scratch disease: response to *Bartonella henselae* in children and a review of diagnostic methods. Eur J Clin Microbiol Infect Dis. 2001;20:392-401.
70. Vermeulen MJ, Verbakel H, Notermans DW, Reimerink JH, Peeters MF. Evaluation of sensitivity, specificity and cross-reactivity in *Bartonella henselae* serology. J Med Microbiol. 2010;59:743-45.
71. La Scola B, Raoult D. Serological cross-reactions between *Bartonella quintana*, *Bartonella henselae*, and *Coxiella burnetii*. J Clin Microbiol. 1996;34:2270-74.
72. Vermeulen MJ, Herremans M, Verbakel H, Bergmans AMC, Roord JJ, vanDijken P, et al. Serological testing for *Bartonella henselae* in the Netherlands: Clinical evaluation of immunofluorescence assay and ELISA. Clin Microbiol Infect. 2007;13:627-34.
73. Tsuruoka K, Tsuneoka H, Kawano M, Yanagihara M, Nojima J, Tanaka T, et al. Evaluation of IgG ELISA using N-lauroyl-sarcosine-soluble proteins of *Bartonella henselae* for highly specific serodiagnosis of cat scratch disease. Diagn Microbiol Infect Dis. 2012;74:230-35.
74. Maggi RG, Duncan AW, Breitschwerdt EB. Novel chemically modified liquid medium that will support the growth of seven *Bartonella* species. J Clin Microbiol. 2005;43:2651-55.
75. Duncan AW, Maggi RG, Breitschwerdt EB. A combined approach for the enhanced detection and isolation of *Bartonella* species in dogs blood samples: pre-enrichment liquid culture followed by PCR and subculture onto agar plates. J Microbiol Methods. 2007;69:273-81.
76. Diaz MH, Bai Y, Malania L, Winchell JM, Kosoy MY. Development of a novel genus-specific real-time PCR assay for detection and differentiation of *Bartonella* species and genotypes. J Clin Microbiol. 2012;50:1645-49.
77. Cadenas MB, Maggi RG, Diniz PP, Breitschwerdt KT, Sontakke S, Breitschwerdt EB. Identification of bacteria from clinical samples using *Bartonella* alpha-proteobacteria growth medium. J Microbiol Methods. 2007;71:147-55.
78. Guptill L. Bartonellosis. Vet Microbiol. 2010;140:347-59.
79. Bowers TJ, Sweger D, Jue D, et al. Isolation, sequencing and expression. Of the gene encoding a major protein from the bacteriophage associated with *Bartonella henselae*. Gene. 1998;206:49-52.
80. La Scola B, Zeaiter Z, Khamis A, Raoult D. Gene-sequence based criteria for species definition in bacteriology: the *Bartonella* paradigm. Trends Microbiol. 2003;11:318-21.
81. Kosoy M, Hayman DTS, Chan KS. *Bartonella* bacteria in nature: where does population variability end and a species start? Infect Genet Evol. 2012;12:894-904.
82. Chang C-C, Chomel B, Kasten RW, Tappero JW, Sanchez M, Koehler JE. Molecular epidemiology of *Bartonella henselae* infection in human immunodeficiency virus-infected patients and their cat contacts using pulsed-field gel electrophoresis and genotyping. J Infect Dis, 2002;186:1733-39.
83. Fan Z, Chaloner G, Darby A, Xiu-ping S, Dong-mei L, Birtles R, Qi-yong L. Optimization of *Bartonella henselae* multilocus sequence typing scheme using single nucleotide polymorphism analysis of Solid sequence data. Chin Med. 2012;125:2284-88.
84. Iredell J, Blanckenberg D, Arvand D, Grauling S, Feil EJ, Birtles RJ. Characterization of the natural population of *Bartonella henselae* by multilocus sequence typing. J Clin Microbiol, 2003;41:5071-79.

85. Voth DE, Heinzen RA. Lounging in a lysosome: the intracellular lifestyle of *Coxiella burnetii*. *Cell Microbiol.* 2007;9(4):829-40.
86. Fournier PE, Marrie TJ, Raoult D. Minireview Diagnosis of Q fever. *J Clin Microbiol.* 1998;36:1823-34.
87. Raoult D, Marrie T. Q fever. *Clin Infect Dis.* 1995;20(3):489-95.
88. Raoult D, Levy PI, Dupont HT, Chicheportiche C, Tamalet C, Gastaut JA, Salducci J. Q fever and HIV infection. *AIDS.* 1993;7:81-86.
89. Center for Disease Control and Prevention (CDC). Q fever. Atlanta, USA [updated January 18, 2011; cited 2011]. Available from: <http://www.cdc.gov/qfever/index.html>
90. Fenollar F, Fournier PE, Raoult D. Molecular Detection of *Coxiella burnetii* in the sera of patients with Q fever endocarditis or vascular infection. *J Clin Microbiol.* 2004;42(11):4919-4924.
91. Raoult D, Parola P. Rickettsial diseases. 1st ed. Informa healthcare. 400 pp. 2007. eBook ISBN 9781420019971.
92. Cunha BA, Nausheen S, Busch L. Severe Q fever community-acquired pneumonia (CAP) mimicking Legionnaires' disease: Clinical significance of cold agglutinins, anti-smooth muscle antibodies and thrombocytosis. *Heart Lung.* 2009;38:354-62.
93. Tissot-Dupont H, Raoult D. Q fever. *Infect Dis Clin North Am.* 2008;22(3):505-14, ix.
94. Olson JG, Mcdade J. *Rickettsia and Coxiella*. In Murray PR. *Manual of Clinical Microbiology.* 6. ed. ASM PRESS, Washington. 1994;678-84.
95. Brouqui P, Marrie TJ, Raoult D. *Coxiella*. In Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Tenover FC, Tenover FC. *Manual of Clinical Microbiology,* ASM PRESS, Washington, 2003;1030-36.
96. Angelakis E, Raoult D. Review Q fever. *Vet Microbiol.* 2010;140:297-309.
97. Frankel D, Richet H, Renvoisé A, Raoult D. Q fever in France, 1985-2009. *Emerg Infect Dis.* 2011;17(3):350-6.
98. Montes M, Cilla G, Vicente D, Ercibengoa M, Perez-Trallero E. Gipuzkoa, Basque Country, Spain (1984-2004), a Hyperendemic area of Q fever. *Ann N Y Acad Sci.* 2006;1078:129-132.
99. Van der Hoek W, Dijkstra F, Schimmer B, Schneeberger PM, Vellema P, Wijkmans C, et al. Q fever in the Netherlands: an update on the epidemiology and control measures. *Euro Surveill.* 2010.15;(12):pii19520. Available: <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19520>
100. Hilbert A, Reith P, Brockmann SO, Tyczka J, Fischer SF, Piechotowski I, et al. Epidemiological enquiries in two Q fever outbreaks in a community of Baden-Württemberg during 2008 and 2009. *Berl Munch Tierarztl Wochenschr.* 2011;124(7-8):295-302.
101. Roest HI, Tilburg JJ, van der Hoek W, Vellema P, van Zijderveld FG, Klaassen CH, Raoult D. The Q fever epidemic in The Netherlands: history, onset, response and reflection. *Epidemiol Infect.* 2011;139(1):1-12.
102. Sprong H, Tjisse-Klasen E, Langelaar M, De Bruin A, Fonville M, Gassner F, et al. Prevalence of *Coxiella burnetii* in Ticks After a Large Outbreak of Q Fever. *Zoonoses Public Health;* 2011. [Epub ahead of print] doi: 10.1111/j.1863-2378.2011.01421.x
103. Whelan J, Schimmer B, DE Bruin A, VAN Beest Holle MR, VAN DER Hoek W, Ter Schegget R. Visits on 'lamb-viewing days' at a sheep farm open to the public was a risk factor for Q fever in 2009. *Epidemiol Infect.* 2011;11:1-7.
104. Bélec L, Ekala M-T, Gilquin J *Coxiella burnetii* infection among HIV-1-infected people living in Paris, France. *AIDS.* 1993;7(8):1136-7.
105. Stein A, Raoult D. Q fever endocarditis. *Eur Heart J.* 1995;16(Suppl B):19-23.
106. Lamas CC, Eykyn SJ. Blood culture negative endocarditis: analysis of 63 cases presenting over 25 years. *Heart.* 2003;89:258-62.

107. Karagiannis I, Morroy G, Rietveld A, Horrevorts AM, Hamans M, Francken P, Schimmer B. A Q fever outbreak in the Netherlands: a preliminary report. *Eurosurveillance*. 2007;12(32):pii=3247.
108. Cilla G, Montes M, Pérez-Trallero E. Q fever in the Netherlands – what matters is seriousness of disease rather than quantity. *Eurosurveillance*. 2008;13(37):pii=18975.
109. Schimmer B, Morroy G, Dijkstra F, Schneeberger PM, Weers-Pothoff G, Timen A, Wijkmans C, van der Hoek W. Large ongoing Q fever outbreak in the south of The Netherlands. *Eurosurveillance*. 2008;13(31):pii=18939.
110. Karagiannis I, Schimmer B, Van Lier A, Timen A, Schneeberger P, Van Rotterdam B, et al. Investigation of a Q fever outbreak in a rural area of The Netherlands. *Epidemiol Infect*. 2009;137(9):1283-94.
111. Delsing CE, Kullberg BJ, Bleeker-Rovers CP. Q fever in the Netherlands from 2007 to 2010. *Neth J Med*. 2010;68(12):382-87.
112. Enserink M. Questions Abound in Q-Fever Explosion in the Netherlands. *Science*. 2010;327(5963):266-67.
113. Van den Wijngaard CC, van Pelt W, Nagelkerke NJ, Kretzschmar M, Koopmans MP. Evaluation of syndromic surveillance in the Netherlands: its added value and recommendations for implementation. *Euro Surveill*. 2011;16(9):pii=19806. Available from: <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19806>
114. Van der Hoek W, Meekelenkamp JC, Leenders AC, Wijers N, Notermans DW, Hukkelhoven CW. Antibodies against *Coxiella burnetii* and pregnancy outcome during the 2007-2008 Q fever outbreaks in The Netherlands. *BMC Infect Dis*. 2011;11:44.
115. Van der Hoek W, Versteeg B, Meekelenkamp JC, Renders NH, Leenders AC, Weers-Pothoff I, et al. Follow-up of 686 patients with acute Q fever and detection of chronic infection. *Clin Infect Dis*. 2011;52(12):1431-36.
116. Klaassen CHW, Nabuurs-Franssen MH, Tilburg JJHC, Hamans MAWM, Horrevorts AM. Multigenotype Q fever outbreak, the Netherlands. *Emerg Infect Dis*. 2009;15(4):613–14.
117. Brandão H, Ribeiro do Valle LA, Christovão DA. Investigação sobre a febre Q em São Paulo. 1. Estudo sorológico em operários de um frigorífico. *Arq Fac Hig Saúde Publ Univ São Paulo*. 1953;7:127-34.
118. Costa PS, Brigatte ME, Greco DB. Questing one Brazilian query: reporting 16 cases of Q fever from Minas Gerais, Brazil. *Rev Inst Med trop S Paulo*. 2006;48(1):5-9.
119. Lamas CC, Rozental T, Bóia MN, Favacho AR, Kirsten AH, da Silva AP, de Lemos ER. Seroprevalence of *Coxiella burnetii* antibodies in human immunodeficiency virus-positive patients in Jacarepaguá, Rio de Janeiro, Brazil. *Clin Microbiol Infect*. 2009;Suppl 2:140-41.
120. Ribeiro do Valle LA, Bassoi ON, Castro RM, Ferreira JM 1955. Febre Q em São Paulo. Primeiro caso confirmado por estudos sorológicos. *Rev Paul Med*. 46(6):447-56.
121. Riemann HP, Brant PC, Franti CE, Reis R, Buchanan AM, Stormont C, Behymer DE. Antibodies to *Toxoplasma gondii* and *Coxiella burnetii* among students and other personnel in veterinary colleges in California and Brazil. *Am J Epidemiol*. 1974;100(3):197-208.
122. Siciliano RF, Ribeiro HB, Furtado RHM, Castelli JB, Sampaio RO, Santos FCP, et al. Endocarditis due to *Coxiella burnetii* (Q fever): a rare or little diagnosed disease? Case report. *Rev Soc Bras Med Trop*. 2008;41(4):409-12.
123. Travassos J, Ubatuba A, Silva NP, Mello MT. Febre Q no Rio de Janeiro. *Cienc e Cult*. 1954;6:199-200.
124. Lemos ER, Rozental T, Mares-Guia MA, Almeida DN, Moreira N, Silva RG, Barreira JD, Lamas CC, Favacho AR, Damasco PV. Q fever as a cause of fever of unknown

- origin and thrombocytosis: first molecular evidence of *Coxiella burnetii* in Brazil. *Vector Borne Zoonotic Dis.* 2011;11(1):85-7.
125. Mares-Guia MAMM. 2011. Febre Q no Município de Itaboraí, Rio de Janeiro: um estudo sorológico e molecular em amostras humanas, de animais vertebrados e de artrópodes em área de ocorrência de caso. Rio de Janeiro. Mestrado [Dissertação em Medicina Tropical] - Instituto Oswaldo Cruz.
 126. Rozental, T, Mascarenhas, LF, Rozenbaum, R, Gomes et al. *Coxiella burnetii*, the agent of Q fever in Brazil: its hidden role in seronegative arthritis and the importance of molecular diagnosis based on the repetitive element IS1111 associated with the transposase gene. *Mem Inst Oswaldo Cruz.* 2012;107:695-97.
 127. Rodolakis A. Q Fever in Dairy Animals. *Rickettsiology and Rickettsial Diseases-Fifth International Conference: Ann NY Acad Sci.* 2009;1166:90–93.
 128. Arricau-Bouvery N, Rodolakis A. Is Q Fever an emerging or re-emerging zoonosis? *Vet Res.* 2005;36:327–49.
 129. Hoover TA, Vodkin MH, Williams JC. A *Coxiella burnetii* repeated DNA element resembling a bacterial insertion sequence. *J Bacteriol.* 1992;174(17):5540-48.
 130. Hendrix LR, Chen C. Antigenic Analysis for Vaccines and Diagnostics. In: Toman R; Heinzen RA; Samuel JE; Mege J-L. (Eds.) *Coxiella burnetii: Recent Advances and New Perspectives in Research of the Q Fever Bacterium Adv Exp Med Biol.* 2012;984:299-396.
 131. Klee SR, Ellerbrok H, Tyczka J, Franz T, Appel B. Evaluation of a real-time PCR assay to detect *Coxiella burnetii*. *Ann N Y Acad Sci.* 2006;1078:563-65.
 132. Fenollar F, Raoult D. Molecular diagnosis of bloodstream infections caused by non-cultivable bacteria. *Int J Antimicrob Agents.* 2007;30 Suppl 1:S7-15.
 133. Massung RF, Cutler SJ, Frangoulidis D. Molecular Typing of *Coxiella burnetii* (Q Fever). In: Toman, R.; Heinzen, R.A.; Samuel, J.E.; Mege, J.-L. (Eds.) *Coxiella burnetii: Recent Advances and New Perspectives in Research of the Q Fever Bacterium. Adv Exp Med Biol.* 2012;984:381-96.
 134. Gnanasegaran G, Croasdale J, Buscomebe JR. Nuclear medicine in imaging infection and inflammation: Part-I, radiopharmaceuticals. *World J Nucl Med.* 2004;3:155-65.
 135. Wareham D, Michael J and Das S. Advances in Bacterial Specific Imaging. *Braz Arch Biol Technol.* 2005;48:145-52.
 136. Welling MM, Lupetti A, Balter HS, Lanzzeri S, Souto B, Rey AM, Savio EO, Paulusma-Annema A, Pauwels EK, Nibbering PH. 99mTc-labeled antimicrobial peptides for detection of bacterial and *Candida albicans* infections. *J Nucl Med.* 2001;42:788-94.
 137. Assadi M, Vahdat K, Nabipour I, Sehhat MR, Hadavand F, Javadi H, Tavakoli A, Saberifard J, Kalantarhormozi MR, Zakani A, Eftekhari M. Diagnostic value of 99mTc-ubiquicidin scintigraphy for osteomyelitis and comparisons with 99mTc-methylene diphosphonate scintigraphy and magnetic resonance imaging. *Nucl Med Commun.* 2011;32:716-23.
 138. Bettgowda C, Foss CA, Cheong I, Wang Y, Diaz L, Agrawal N, Fox J, Dick J, Dang LH, Zhou S, Kinzler KW, Vogelstein B, Pomper MG. Imaging bacterial infections with radiolabeled 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranocyl)-5-iodouracil. *Proc Natl Acad Sci USA.* 2005;102:1145-50.
 139. Pullambhatla M, Tessier J, Beck G, Jedynek B, Wurthner JU, Pomper MG. [¹²⁵I]FIAU imaging in a preclinical model of lung infection: quantification of bacterial load. *Am J Nucl Med Mol Imaging.* 2012;2:260-70.
 140. Viu J, Monreal L, Jose-Cunilleras E, Cesarini C, Añor S, Armengou L. Clinical findings in 10 foals with bacterial meningoencephalitis. *Equine Vet J Suppl.* 2012;44(Suppl 41):100-4.

141. Yu CW, Hsiao JK, Hsu CY, Shih TT. Bacterial pyomyositis: MRI and clinical correlation. *Magn Reson Imaging*. 2004;22(9):1233-41.
142. Morais LT, Zanardi Vde A, Faria AV. Magnetic resonance spectroscopy in the diagnosis and etiological definition of brain bacterial abscesses. *Arq Neuropsiquiatr*. 2007;65:1144-48.
143. Wang J, Zhang X, Zhou D, Wang Q, Li D, Magnetic resonance imaging (MRI) in detection of *Bifidobacterium longum* and *Clostridium novyi-NT* labelled with superparamagnetic iron oxide (SPIO) nanoparticle. *Naturepreceedings*; 2009. Available at <http://preceedings.nature.com/documents/3435/version/1> (accessed March 2013).
144. Righi V, Starkey M, Rahme LG, Tompkins RG, Tzika AA. Magnetization Transfer Contrast MRI detects *Pseudomonas aeruginosa* bacterial infection *bacterial infection* a mouse burn model. *Proc Intl Soc Mag Reson Med*. 2011;19:662.
145. Leevy WM, Gammon ST, Jiang H, Johnson JR, Maxwell DJ, Jackson EN, Marquez M, Piwnicka-Worms D, Smith BD. Optical Imaging of Bacterial Infection in Living Mice Using a Fluorescent Near-Infrared Molecular Probe. *J Am Chem Soc*. 2006;128:16476-77.
146. McClintic J, Srivastava S. Imaging in the Diagnosis and management of ocular cat scratch disease. *Int Ophthalmol Clin*. 2012;4:155-61.
147. Sampath R, Hall TA, Massire C, Li F, Blyn LB, Eshoo MW, Hofstadler SA, Ecker DJ. Rapid Identification of Emerging Infectious Agents Using PCR and Electrospray Ionization Mass Spectrometry, *Ann NY Acad Sci*. 2007;1102:109–20.
148. Honisch C, Chen Y, Mortimer C, Arnold C, Schmidt O, van den Broom D, et al. Automated comparative sequence analysis by base-specific cleavage and mass spectrometry for nucleic acid-based microbial typing. *PNAS*. 2007;104:10649-54.
149. Sauer S, Freiwald A, Maier T, Kube M, Reinhardt R, Kostrzewa M, Geider K. Classification and identification of bacteria by mass spectrometry and computational analysis. *PLoS ONE* 2008;3(7):e2843.
150. Eshoo MW, Crowder CD, Li H, Matthews HE, Meng S, Sefers SE et al. Detection and Identification of *Ehrlichia* Species in Blood by Use of PCR and Electrospray Ionization Mass Spectrometry. *J Clin Microbiol*. 2010;48:472-78.
151. Puzey KA, Gardner PJ, Petrova VK, Donnelly CW, Petrucci GA. Automated species and strain identification of bacteria in complex matrices using FTIR spectroscopy. *Proc. SPIE* 6954, Chemical, Biological, Radiological, Nuclear, and Explosives (CBRNE) Sensing IX, 695412 (April 17, 2008)
152. Kim S, Burgula Y, Ojanen-Reuhs T, Cousin MA, Reuhs BL, Mauer LJ, Differentiation of Crude Lipopolysaccharides from *Escherichia coli* Strains Using Fourier Transform Infrared Spectroscopy and Chemometrics, *J Food Sci*. 2006;71:M57-M61.
153. Burgula Y, Khali D, Kim S, Krishnan SS, Cousin MA, Gore JP, Reuhs BL, Mauer LJ. Detection of *Escherichia coli* O157:H7 and *Salmonella* Typhimurium using filtration followed by Fourier transform infrared spectroscopy. *J Food Prot*. 2006;69:1777–84.
154. Burgula Y, Reuhs BL, Mauer LJ. Rapid FT-IR methods for detection of *Escherichia coli* O157:H7 in fruit juices. *World food science* 2006, available at http://www.worldfoodscience.org/pdf/FTIR_7.pdf (accessed March 2013).
155. Davis R, Irudayaraj J, Reuhs BL, Mauer LJ. Detection of *E.coli* O157:H7 from ground beef using Fourier Transform Infrared (FT-IR) Spectroscopy and Chemometrics. *J Food Sci*. 2010;75:M340-M346.
156. Davis R, Burgula Y, Deering A, Irudayaraj J, Reuhs BL, Mauer LJ, Detection and differentiation of live and heat-treated *Salmonella entericaserovars* inoculated onto chicken breast using Fourier transform infrared (FT-IR) spectroscopy. *J Appl Microbiol*. 2010;109:2019-31.

157. Davis R, Deering A, Burgula Y, Mauer LJ, Reuhs BL. Differentiation of live, dead and treated cells of *Escherichia coli* O157:H7 using FT-IR spectroscopy. *J Appl Microbiol.* 2012;112:743-51.
158. Davis R, Mauer LJ. Subtyping of *Listeria monocytogenes* at the haplotype level by Fourier transform infrared (FT-IR) spectroscopy and multivariate statistical analysis. *Int J Food Microbiol.* 2011;150:140-49.
159. Davis R, Paoli G, Mauer LJ. Evaluation of Fourier transform infrared (FT-IR) spectroscopy and chemometrics as a rapid approach for subtyping *E. coli* O157:H7 isolates. *Food Microbiol.* 2012;31:181-90.
160. Ravindranath SP, Mauer LJ, DebRoy C, and Irudayaraj J. Bio-functionalized magnetic nanoparticle integrated mid-IR pathogen sensor for food matrices. *Anal Chem.* 2009;81(8):2840-46.
161. Mura S, Greppi G, Marongiu ML, Roggero PR, Ravindranath SP, Mauer LJ, et al. FTIR nanobiosensors for *Escherichia coli* detection. *Beilstein J Nanotechnol.* 2012;3:485-92.
162. Disney MD, Seeberger PH. The use of carbohydrate microarrays to study carbohydrate-cell interactions and to detect pathogens. *Chem Biol.* 2004;11:1701-07.
163. Wang DN, Liu SY, Trummer BJ, Deng C, Wang AL. Carbohydrate microarrays for the recognition of cross-reactive molecular markers of microbes and host cells. *Nat Biotechnol.* 2002;20:275-81.
164. Hsu KL, Pilobello KT, Mahal LK. Analyzing the dynamic bacterial glycome with a lectin microarray approach. *Nature Chem Biol.* 2006;2:153-57.
165. Mahal LK, Pilobello K, and Rishnamoorthy L. Development of a lectin microarray for the glycomic profiling of cells. *Glycobiology.* 2004;14:1203-06.
166. Zheng T, Peelen D, Smith LM. Lectin arrays for profiling cell surface carbohydrate expression. *J Am Chem Soc.* 2005;127:9982-83.
167. Liu H. Pathogenic bacterial sensors based on carbohydrates as sensing elements. In: Zourob M, Elwary S and Turner APF, editors. *Principles of bacterial detection: biosensors, recognition receptors and microsystems*, SpringerLink; 2008.
168. Howell SW, Inerowicz HD, Regnier FE, Reifenger R. Patterned protein microarrays for bacterial detection. *Langmuir.* 2003;19:436-39.
169. Small J, Call DR, Brockman FJ, Straub TM, Chandler DP. Direct detection of 16S rRNA in soil extracts by using oligonucleotide microarrays. *Appl Environ Microbiol.* 2001;67:4708-16.
170. Wilson KH, Wilson WJ, Radosevich JL, DeSantis TZ, Viswanathan VS, Kuczmariski TA, Andersen GL. High-density microarray of small-subunit ribosomal DNA probes. *Appl Environ Microbiol.* 2002;68:2535-41.
171. Yue H, Eastman PS, Wang BB, Minor J, Doctolero MH, Nuttall RL, Stack R, Becker JW, Montgomery JR, Vainer M, Johnston R. An evaluation of the performance of cDNA microarrays for detecting changes in global mRNA expression. *Nucleic Acids Res.* 2001;29:E41.
172. Chizhikov V, Rasooly A, Chumakov K, Levy DD. Microarray analysis of microbial virulence factors. *Appl Environ Microbiol.* 2001;67:3258-63.
173. Volokhov D, Rasooly A, Chumakov K, Chizhikov V. Identification of listeria species by microarray-based assay. *J Clin Microbiol.* 2002;40:4720-28.
174. Naval Medical Research Center. Rickettsial Diseases Division. Accessed 30 March 2013. Available: http://www.med.navy.mil/sites/nmrc/Pages/id_rd.htm
175. Ching WM, Ge H. Diagnostic assay for rickettsia prowazekii disease by detection of responsive gene expression. USPTO Application #20060099628; 2004.

176. Audia JP, Patton MC, Winkler HH. DNA microarray analysis of the heat shock transcriptome of the obligate intracytoplasmic pathogen *Rickettsia prowazekii*. *Appl Environ Microbiol.* 2008;74:7809-12.
177. Bechah Y, Karkouri KE, Mediannikov O, Leroy Q, Pelletier N, Robert C, Medigue C, Mege JL, Raoult D. Genomic, proteomic and transcriptomic analysis of virulent and avirulent *Rickettsia prowazekii* reveals its adaptive mutation capabilities. *Genome Res.* 2010;20:655-63.
178. OligoArrayDb, Accessed 30 March 2013. Available: <http://berry.engin.umich.edu/oligoarraydb/>
179. Ballarini A, Segata N, Huttenhower C, Jousson O. Simultaneous quantification of multiple bacteria by the bactochip microarray designed to target species-specific marker genes. *PLoS ONE.* 2013;8(2):e55764.
180. Kostic T, Francois P, Bodrossy L, Schrenzel J. Oligonucleotide and DNA microarrays: versatile tools for rapid bacterial diagnostics. In: Zourob M, Elwary S and Turner APF, editors. *Principles of bacterial detection: biosensors, recognition receptors and Microsystems.* SpringerLink; 2008.
181. Mossoba MM, Al-Khaldi SF, Kirkwood J, Fry FS, Sedman J, Ismail AA. Printing microarrays of bacteria for identification by infrared microspectroscopy. *Vib Spectrosc.* 2005;38:229-35.
182. Al-Khaldi SF, Mossoba MM, Allard MM, Lienau EK, Brown ED. Bacterial detection and subtyping using DNA microarray and DNA sequencing. *Methods Mol Biol.* 2012;881:73-95.
183. Elsholz B, Worl R, Blohm L, Albers J, Feucht H, Grunwald T, Jurgen B, Schweder T and Hintsche R. Automated detection and quantification of bacterial RNA by using electrical microarrays. *Anal Chem.* 2006;78:4794-802.
184. Leonard P, Hearty S, Brennan J, Dunne L, Quinn J, Chakraborty T, O'Kennedy R. Advances in biosensors for detection of pathogens in food and water. *Enzyme Microb Technol.* 2003;32:3-13.
185. Zourob M, Elwary S, Turner APF, editors. *Principles of bacterial detection: biosensors, recognition receptors and microsystems,* SpringerLink; 2008.
186. Taylor AD, Ladd J, Homola J, Jiang S. Surface plasmon resonance (SPR) sensors for the detection of bacterial pathogens. In: Zourob M, Elwary S and Turner APF, editors. *Principles of bacterial detection: biosensors, recognition receptors and Microsystems.* SpringerLink; 2008.
187. Sapsford KE, Shriver-Lake LC. Bacterial detection using evanescent wave-based fluorescent biosensors. In: Zourob M, Elwary S and Turner APF, editors. *Principles of bacterial detection: biosensors, recognition receptors and Microsystems.* SpringerLink; 2008.
188. Hayman RB. Fiber optic biosensors for bacterial detection. In: Zourob M, Elwary S and Turner APF, editors. *Principles of bacterial detection: biosensors, recognition receptors and Microsystems.* SpringerLink; 2008.
189. Zourob M, Skivesen N, Horvath R, Mohr S, McDonnell MB. Integrated deep-probe optical waveguides for label free bacterial detection. In: Zourob M, Elwary S and Turner APF, editors. *Principles of bacterial detection: biosensors, recognition receptors and Microsystems.* SpringerLink; 2008.
190. Campbell DP. Interferometric biosensors. In: Zourob M, Elwary S and Turner APF, editors. *Principles of bacterial detection: biosensors, recognition receptors and microsystems.* SpringerLink; 2008.

191. Farris L, Habteselassie MY, Perry L, Chen Y, Turco R. Luminescence techniques for the detection of bacterial pathogens. In: Zourob M, Elwary S and Turner APF, editors. Principles of bacterial detection: biosensors, recognition receptors and Microsystems. SpringerLink; 2008.
192. Mace CR, Miller BL. Porous and Planar Silicon Sensors. In: Zourob M, Elwary S and Turner APF, editors. Principles of bacterial detection: biosensors, recognition receptors and Microsystems. SpringerLink; 2008.
193. Olsen E, Vainrub A, Vodyanoy V. Acoustic wave (TSM) biosensors: weighing bacteria. In: Zourob M, Elwary S and Turner APF, editors. Principles of bacterial detection: biosensors, recognition receptors and Microsystems. SpringerLink; 2008.
194. Palchetti I, Mascini M. Amperometric biosensor for pathogenic bacteria detection. In: Zourob M, Elwary S and Turner APF, editors. Principles of bacterial detection: biosensors, recognition receptors and Microsystems. SpringerLink; 2008.
195. Miyahara Y, Sakata T, Matsumoto A. Microbial genetic analysis based on field effect transistors. In: Zourob M, Elwary S and Turner APF, editors. Principles of bacterial detection: biosensors, recognition receptors and Microsystems. SpringerLink; 2008.
196. Munoz-Berbel X, Godino N, Laczka O, Baldrich E, Munoz FX. Impedance-based biosensors for pathogen detection. In: Zourob M, Elwary S and Turner APF, editors. Principles of bacterial detection: biosensors, recognition receptors and Microsystems. SpringerLink; 2008.
197. Alocilja E, Muhammad-Tahir Z. Label-Free Microbial biosensors using molecular nanowire transducers. In: Zourob M, Elwary S and Turner APF, editors. Principles of bacterial detection: biosensors, recognition receptors and Microsystems. SpringerLink; 2008.
198. Haik Y, Sawafta R, Ciubotaru I, Qablan A, Tan EL, Ong KG. Magnetic techniques for rapid detection of pathogens. In: Zourob M, Elwary S and Turner APF, editors. Principles of bacterial detection: biosensors, recognition receptors and Microsystems. SpringerLink; 2008.
199. Mutharasan R. Cantilever sensors for pathogen detection. In: Zourob M, Elwary S and Turner APF, editors. Principles of bacterial detection: biosensors, recognition receptors and Microsystems. SpringerLink; 2008.
200. Grow AE. Label-Free Fingerprinting of pathogens by raman spectroscopy techniques. In: Zourob M, Elwary S and Turner APF, editors. Principles of bacterial detection: biosensors, recognition receptors and Microsystems. SpringerLink; 2008.
201. Banada PP, Bhunia AK. Antibodies and immunoassays for detection of bacterial pathogens. In: Zourob M, Elwary S and Turner APF, editors. Principles of bacterial detection: biosensors, recognition receptors and Microsystems. SpringerLink; 2008..
202. Glynn B. Rapid nucleic acid-based diagnostics methods for the detection of bacterial pathogens. In: Zourob M, Elwary S and Turner APF, editors. Principles of bacterial detection: biosensors, recognition receptors and Microsystems. SpringerLink; 2008.
203. Fowler CC, Navani NK, Brown ED, Li Y. Aptamers and their potential as recognition elements for the detection of bacteria. In: Zourob M, Elwary S and Turner APF, editors. Principles of bacterial detection: biosensors, recognition receptors and Microsystems. SpringerLink; 2008.
204. Warriner K, Lai EPC, Namvar A, Hawkins DM, Reddy SM. Molecularly imprinted polymers for biorecognition of bioagents. In: Zourob M, Elwary S and Turner APF, editors. Principles of bacterial detection: biosensors, recognition receptors and Microsystems. SpringerLink; 2008.

205. Gulig PA, Martin JL, Messer HG, Deffense BL. Phage display methods for detection of bacterial pathogens. In: Zourob M, Elwary S and Turner APF, editors. Principles of bacterial detection: biosensors, recognition receptors and Microsystems. SpringerLink; 2008.
206. Schmelcher M, Loessner MJ. Bacteriophage: powerful tools for the detection of bacterial pathogens. In: Zourob M, Elwary S and Turner APF, editors. Principles of bacterial detection: biosensors, recognition receptors and Microsystems. SpringerLink; 2008.
207. Smietana M, Bock WJ, Mikulic P, Ng A, Chinnappan R and Zourob M. Detection of bacteria using bacteriophages as recognition elements immobilized on long-period fiber gratings. Opt Express. 2011;19:7971-78.
208. Singh A, Poshtiban S, Evoy S. Recent advances in bacteriophage based biosensors for food-borne pathogen detection. Sensors. 2013;13:1763-86.
209. Lui C, Cady NC, Batt CA. Nucleic acid-based detection of bacterial pathogens using integrated microfluidic platform systems. Sensors. 2009;9:3713-44.
210. Simpson PC, Goode P, Tapsak MA, Carr-Brendel V. Electrochemical sensors including electrode systems with increased oxygen generation. Patent Number 7108778. Filing date 2004.
211. Simpson PC, Petisce JR, Carr-Brendel VE, Brauker JH. Electrode systems for electrochemical sensors. US20120228134 A1, Filing date May 2012.
212. Brister M, Neale PV, Brauker J. Transcutaneous analyte sensor. US 2010/0174164 A1, Filing date March 2010.
213. Hatch A. Ultrasensitive microanalytical diagnostic methods for rickettsial pathogens. Accessed 30 March 2013. Available: http://www.osti.gov/bridge/product.biblio.jsp?osti_id=1035853
214. Bruno J. Handheld aptamer-magnetic bead-quantum dot sensor for rickettsias. Small Business Innovation Research SBIR website, Accessed 30 March 2013. Available: <http://www.sbir.gov/sbirsearch/detail/8253>
215. Borbas KE, Ferreira CSM, Perkins A, Bruce JI, Missailidis S. Design and synthesis of mono- and multimeric targeted radiopharmaceuticals based on novel cyclen ligands coupled to anti-MUC1 aptamers for the diagnostic imaging and targeted radiotherapy of cancer. J Bioconj Chem. 2007;18(4):1205-12.
216. DaPieve C, Perkins AC, Missailidis S. Anti-MUC1 aptamers: radiolabelling with ^{99m}Tc and biodistribution in MCF-7 tumour-bearing mice. Nuclear Med Biol. 2009;36:703-10.
217. Li Y, Lee HJ, Corn RM. Detection of protein biomarkers using RNA aptamer microarrays and enzymatically amplified surface plasmon resonance imaging. Anal Chem. 2007;79(3):1082-88.
218. Ahn JY, Lee SW, Kang HS, Jo M, Lee D, Laurell T, Kim S. Aptamer microarray mediated capture and mass spectrometry identification of biomarker in serum samples. J Proteome Res. 2010; 9:5568-73.
219. Velasco-Garcia MN, Missailidis S. New trends in aptamer-based electrochemical biosensors. Gene Ther Mol Biol. 2009;13:1-10.
220. Ferreira CSM, Papamichael K, Guilbault G, Schwarzacher T, Garipey J, Missailidis S. DNA aptamers against MUC1: design of aptamer-antibody sandwich ELISA for early tumour diagnosis. Anal Bioanal Chem. 2008;390(4):1039-50.
221. Vivekananda J, Kiel JL. Anti-*Francisella tularensis* DNA aptamers detect tularemia antigen from different subspecies by aptamer-linked immobilized sorbent assay. Lab Invest. 2006;86:610-18.
222. Labib M, Zamay AS, Kolovskaya OS, Reshetneva IT, Zamay GS, Kibbee RJ, Sattar SA, Zamay TN, Berezovski MV. Aptamer-based impedimetric sensor for bacterial typing. Anal Chem. 2012;84(19):8114-17.

223. Hyeon JY, Chon JW, Choi IS, Park C, Kim DE, Seo KH. Development of RNA aptamers for detection of *Salmonella enteritidis*. J Microbiol Methods. 2012;89(1):79-82.
224. Maeng JS, Kim N, Kim CT, Han SR, Lee YJ, Lee SW, Lee MH, Cho YJ. Rapid detection of food pathogens using RNA aptamers-immobilized slide. J Nanosci Nanotechnol. 2012;12(7):5138-42.
225. Li H, Ding X, Peng Z, Deng L, Wang D, Chen H, He Q. Aptamer selection for the detection of *Escherichia coli* K88. Can J Microbiol. 2011;57(6):453-59.
226. Duan N, Wu S, Zhu C, Ma X, Wang Z, Yu Y, Jiang Y. Dual-color upconversion fluorescence and aptamer-functionalized magnetic nanoparticles-based bioassay for the simultaneous detection of *Salmonella typhimurium* and *Staphylococcus aureus*. Anal Chim Acta. 2012;723:1-6.
227. Fan M, McBurnett SR, Andrews CJ, Allman AM, Bruno JG, Kiel JL. Aptamer selection express: a novel method for rapid single-step selection and sensing of aptamers. J Biomol Tech. 2008;19:311-19.
228. Wang KY, Zeng YL, Yang XY, Li WB, Lan XP. Utility of aptamer-fluorescence in situ hybridization for rapid detection of *Pseudomonas aeruginosa*. Eur J Clin Microbiol Infect Dis. 2011;30(2):273-78.
229. Ohk SH, Koo OK, Sen T, Yamamoto CM, Bhunia AK. Antibody-aptamer functionalized fibre-optic biosensor for specific detection of *Listeria monocytogenes* from food. J Appl Microbiol. 2010;109(3):808-17.
230. Moldenhauer, J. Overview of rapid microbiological methods. In: Zourob M, Elwary S and Turner APF, editors. Principles of bacterial detection: biosensors, recognition receptors and Microsystems. SpringerLink; 2008.

© 2014 Missailidis et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:
<http://www.sciencedomain.org/review-history.php?iid=321&id=19&aid=2572>